Antonie van Leeuwenhoek

, Volume 58, Issue 1, pp 1–47

Immunogenicity and immunochemistry ofStreptococcus pneumoniae capsular polysaccharides

  • Jan E. G. van Dam
  • André Fleer
  • Harm Snippe
Review

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ada GL (1987) General discussion. In: Bell R & Torrigiani G (Eds) Towards Better Carbohydrate Vaccines. (pp 335–354) J. Wiley & Sons LtdGoogle Scholar
  2. Adeyeye A, Jansson P-E, Lindberg B & Henrichsen J (1988) Structural studies of the capsular polysaccharide fromStreptococcus pneumoniae type 37. Carbohydr. Res. 180: 295–299CrossRefGoogle Scholar
  3. Amvam-Zollo PH & Sinaÿ P (1986)Streptococcus pneumoniae type XIV polysaccharide: synthesis of a repeating branced tetrasaccharide with dioxa-type spacer-arms. Carbohydr. Res. 150: 199–212CrossRefPubMedGoogle Scholar
  4. Anderson P (1983) Antibody responses toHaemophilus influenzae type b and diphtheria toxin induced by conjugates of oligosaccharides of the type b capsule with the nontoxic protein CRM197. Infect. Immun. 39: 233–238PubMedGoogle Scholar
  5. Andersson B, Dahmén J, Frejd T, Leffler H, Magnusson G, Noori G & Svanborg-Edén C (1983a) Identification of an active disaccharide unit of a glycoconjugate receptor for pneumococci attaching to human pharyngeal epithelial cells. J. Exp. Med. 158: 559–570CrossRefPubMedGoogle Scholar
  6. Andersson B, Ericksson B, Falsen E, Fogh A, Hanson LÅ, Nylén O, Peterson H & Svanborg-Edén C (1983b) Adhesion ofStreptococcus pneumoniae to human pharyngeal epithelial cells in vitro: differences in adhesive capacity among strains isolated from subjects with otitis media, septicemia, or meningitis or from healthy carriers. Infect. Immun. 32: 311–317Google Scholar
  7. Andersson B, Porras O, Hanson LÅ & Svanborg-Edén C (1985) Non-antibody-containing fractions of breast milk inhibit epithelial attachment ofStreptococcus pneumoniae andHaemophilus influenzae. Lancet 1: 643PubMedGoogle Scholar
  8. Andersson B, Beachey EH, Tomasz A, Tuomanen E & Svanborg-Edén C (1988) A sandwich adhesion onStreptococcus pneumoniae attaching to human oropharyngeal epithelial cells in vitro. Microbial Pathogen 4: 276–278CrossRefGoogle Scholar
  9. Aniansson G, Andersson B & Svanborg-Edén C (1988) Abstr. XIVth Int. Carbohydr. Symp., Stockholm, p 369Google Scholar
  10. Applebaum PC (1987) World-wide development of antibiotic resistance in pneumococci. Eur. J. Clin. Microbiol. 6: 367–377Google Scholar
  11. Applebaum PC, Bhamjee A, Scragg JN, Hallett AF, Bowen AJ & Cooper RC (1977)Streptococcus pneumoniae resistant to penicillin and chloramphenicol. Lancet 2: 995–997Google Scholar
  12. Ashwell JD & Schwartz RH (1986) T-cell recognition of antigen and the Ia molecule as a ternary complex. Nature 320: 176–179CrossRefPubMedGoogle Scholar
  13. Au CC & Eisenstein TK (1981a) Evaluation of the role of the pneumococcal Forssman antigen (F-polysaccharide) in the cross-serotype protection induced by pneumococcal subcellular preparations. Infect. Immun. 31: 169–173PubMedGoogle Scholar
  14. Au CC & Eisenstein TK (1981b) Nature of the cross-protective antigen in subcellular vaccines ofStreptococcus pneumoniae. Infect. Immun. 31: 160–168PubMedGoogle Scholar
  15. Austrian R (1981) Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention. Rev. Infect. Dis. 3: S1–17PubMedGoogle Scholar
  16. Austrian R (1986) Some aspects of the pneumococcal carrier state. J. Antimicrob. Chemother. 18: Suppl. A 35–45PubMedGoogle Scholar
  17. Austrian R (1989) Pneumococcal polysaccharide vaccines. Rev. Infect. Dis. 11: Suppl. 3 S 598–602Google Scholar
  18. Austrian R & Gold J (1964) Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann. Intern. Med. 60: 759–776Google Scholar
  19. Austrian R, Boettger C, Dole M, Fairly L & Freid M (1985)Streptococcus pneumoniae type 16A, a hitherto undescribed pneumococcal type. J. Clin. Microbiol. 22: 127–128PubMedGoogle Scholar
  20. Avery OT & Dubos R (1931) The protective action of a specific enzyme against type III pneumococcus infection in mice. J Exp Med 54: 73–90Google Scholar
  21. Babbitt B, Allen PM, Matsueda G, Haber E & Unanue ER (1985) Binding of immunogenic peptides to Ia histocompatibility molecules. Nature 317: 359–361CrossRefPubMedGoogle Scholar
  22. Bach MA, Beckmann E & Levitt D (1984) Pneumococcal cell wall phosphorylcholine elicits polyclonal antibody secretion in mice. Eur J. Immunol. 14: 589–594PubMedGoogle Scholar
  23. Baker PJ, Stashak PW, Amsbaugh DF & Prescott B (1974a) Regulation of the antibody response to type III pneumococcal polysaccharide. II. Mode of action of thymic derived suppressor cells. J. Immunol. 112: 404–409PubMedGoogle Scholar
  24. Baker PJ, Stashak PW, Amsbaugh DF & Prescott B (1974b) Regulation of the antibody response to type III pneumococcal polysaccharide. IV. Role of suppressor T cells in the development of low-dose paralysis. J. Immunol. 112: 2020–2027PubMedGoogle Scholar
  25. Baker PJ, Amsbaugh DF, Prescott B & Stashak PW (1976) Genetic control of the antibody response to type III pneumococcal polysaccharide in mice. III. Analysis of genes governing the expression of regulatory T cell activity. J. Immunogenet. 3: 275–286PubMedGoogle Scholar
  26. Baker PJ, Amsbaugh DF, Stashak PW, Caldes G & Prescott B (1981) Regulation of the antibody response to pneumococcal polysaccharide by thymus-derived cells. Rev. Infect. Dis. 3: 332–341PubMedGoogle Scholar
  27. Baker PJ, Rudbach JA, Prescott B, Caldes G, Evans C & Stashak PW (1984) Influence of multiple genes on the magnitude of the antibody response to bacterial polysaccharide antigens. Infect. Immun. 45: 56–61PubMedGoogle Scholar
  28. Baker PJ, Hiernaux JR, Fauntleroy MB, Prescott B, Cantrell JL & Rudbach JA (1988a) Inactivation of suppressor T cell activity by nontoxic monophosphoryl lipid A. Infect. Immun. 56: 1076–1083PubMedGoogle Scholar
  29. Baker PJ, Fauntleroy MB, Stashak PW, Hiernaux JR, Prescott B, Cantrell JL & Rudbach JA (1988b) Adjuvant effects of trehalose dimycolate on the antibody response to type III pneumococcal polysaccharide. Infect. Immun. 57: 912–917Google Scholar
  30. Barrett DJ & Ayoub EM (1986) IgG2 subclass restriction of antibody to pneumococcal polysaccharides. Clin. Exp. Immunol. 63: 127–134PubMedGoogle Scholar
  31. Barrett DJ, Lee CG, Ammann AJ & Ayoub EM (1984) IgG and IgM pneumococcal polysaccharide antibody responses in infants. Pediatr. Res. 18: 1067–1071PubMedGoogle Scholar
  32. Barthold DR, Prescott B, Stashak PW, Amsbaugh DF & Baker PJ (1974) Regulation of the antibody response to type III pneumococcal polysaccharide. III. Role of regulatory T cells in the development of an IgG and IgA antibody response. J. Immunol. 112: 1042–1050PubMedGoogle Scholar
  33. Batavyal L & Roy N (1983) Structure of the capsular polysaccharide ofDiplococcus pneumoniae type 31. Carbohydr. Res. 119: 300–302CrossRefGoogle Scholar
  34. Beam TR, Crigler ED, Goldman JK & Schiffman G (1980) Antibody response to polyvalent pneumococcal polysaccharide vaccine in diabetics. J. Amer. Med. Assoc. 244: 2621–2624CrossRefGoogle Scholar
  35. BeBault GM, Dutton GGS, Funnell NA & McKenzie KL (1978) Structural investigation ofKlebsiella serotype 32. Carbohydr. Res. 68: 183–192Google Scholar
  36. Becker GE & Pappenheimer AM (1966) Lyase activity of inducible S8-depolymerases fromBacillus palustris. Biochim. Biophys. Acta 121: 343–348PubMedGoogle Scholar
  37. Bennett LG & Bishop CT (1977) Structure of the type XXVIIStreptococcus pneumoniae (pneumococcal) capsular polysaccharide. Can. J. Chem. 55: 8–16Google Scholar
  38. Bennett LG & Bishop CT (1980) Structure of the type XXXIIIStreptococcus pneumoniae (pneumococcal) capsular polysaccharide. Can. J. Chem. 58: 2724–2727Google Scholar
  39. Benzing L, Carlo DJ & Perry MB (1981) Specific capsular polysaccharide of type 46Streptococcus pneumoniae (American type 73). Infect. Immun. 32: 1024–1027PubMedGoogle Scholar
  40. Berry AM, Yother J, Briles DE, Hansman D & Paton JC (1989a) Reduced virulence of a defined pneumolysin-negative mutant ofStreptococcus pneumoniae. Infect. Immun. 57: 2037–2042PubMedGoogle Scholar
  41. Berry AM, Lock RA, Hansman D & Paton JC (1989b) Contribution of autolysin to virulence ofStreptococcus pneumoniae. Infect. Immun. 57: 2324–2330PubMedGoogle Scholar
  42. Beuth J, Ko H-L, Schroten H, Sölter J, Uhlenbruck G & Pulverer G (1987) Lectin mediated adhesion ofStreptococcus pneumoniae and its specific inhibition in vivo. Zbl. Bakt. Hyg. A 265: 160–168Google Scholar
  43. Beuvery EC, van Rossum F & Nagel J (1982) Comparison of the induction of immunoglobulin M and G antibodies in mice with purified pneumococcal type 3 and meningococcal group C polysaccharides and their protein conjugates. Infect. Immun. 37: 15–22PubMedGoogle Scholar
  44. Bialy H (1987) Recombinant proteins: virtual authenticy. Bio/Technol. 5: 1124Google Scholar
  45. Birgens HS, Espersen F, Hertz JB, Pedersen FK & Drivsholm A (1983) Antibody response to pneumococcal vaccination in patients with myelomatosis. Scand. J. Haematol. 30: 324–330PubMedGoogle Scholar
  46. Björndal H, Lindberg B, Lönngren J, Nimmich W & Rosell K-G (1973) Structural studies of theKlebsiella type 47 capsular polysaccharide. Carbohydr. Res. 27: 373–378CrossRefPubMedGoogle Scholar
  47. Bjornson AB, Lobel JS & Harr KS (1985) Relation between serum opsonic activity forStreptococcus pneumoniae and complement function in sickle cell disease. J. Infect. Dis. 152: 701–709PubMedGoogle Scholar
  48. Bjornson AB & Lobel JS (1986) Lack of requirement for the Fc region of IgG in restoring pneumococcal opsonization via the alternative complement pathway in sickle cell disease. J. Infect. Dis. 154: 760–769PubMedGoogle Scholar
  49. Bjornson AB & Lobel JS (1987) Direct evidence that decreased serum opsonization ofStreptococcus pneumoniae via the alternative complement pathway in sickle cell disease is related to antibody deficiency. J. Clin. Invest. 79: 388–398PubMedGoogle Scholar
  50. Blackwell CC, Jónsdóttir K, Hanson M, Todd WTA, Chaudhuri AKR, Mathew B, Brettle RP & Weir DM (1986) Nonsecretion of ABO antigens predisposing to infections byNeisseria meningitidis andStreptococcus pneumoniae. Lancet 2: 284–285PubMedGoogle Scholar
  51. Borek F (1977) Adjuvants. In: Sela M (Ed) The Antigen, Vol. 4 (pp 374–428) Acad. Pres, New YorkGoogle Scholar
  52. Bortolussi R, Marrie TJ, Cunningham J & Schiffman G (1981) Serum antibody and opsonic responses after immunization with pneumococcal vaccine in kidney transplant recipients and controls. Infect. Immun. 34: 20–25PubMedGoogle Scholar
  53. Braconier JH & Odeberg H (1982) Granulocyte phagocytosis and killing of virulent and avirulent serotypes ofStreptococcus pneumonia. J. Lab. Clin. Med. 100: 279–287PubMedGoogle Scholar
  54. Braconier JH, Odeberg H & Sjöholm AG (1983a) Granulocyte phagocytosis ofStreptococcus pneumoniae in properdin-deficient serum. Infect. Immun. 40: 219–224.PubMedGoogle Scholar
  55. Braconier JH, Myre EB & Odeberg H (1983b) Cross-reacting opsonic antibodies to clinically important pneumococcal serotypes after pneumococcal vaccination. Eur. J. Clin. Microbiol. 2: 453–458CrossRefPubMedGoogle Scholar
  56. Braley-Mullen H (1974) Regulatory role of T cells in IgG antibody formation and immune memory to type III pneumococcal polysaccharide. J. Immunol. 113: 1909–1920PubMedGoogle Scholar
  57. Braley-Mullen H (1982) Activation of distinct subsets of T suppressor cells with type III pneumococcal polysaccharide coupled to syngeneic spleen cells. Ann. N.Y. Acad. Sci. 392: 156–166PubMedGoogle Scholar
  58. Braley-Mullen H (1984) Regulation of the antibody response to type III pneumococcal polysaccharide by contrasuppressor T cells. J. Exp. Med. 160: 42–54CrossRefPubMedGoogle Scholar
  59. Braley-Mullen H (1986a) Requirements for activation of contrasuppressor T cells by type III pneumococcal polysaccharide. J. Immunol. 136: 396–401PubMedGoogle Scholar
  60. Braley-Mullen H (1986b) Characterization and activity of contrasuppressor T cells induced by type III pneumococcal polysaccharide. J. Immunol. 137: 2761–2767PubMedGoogle Scholar
  61. Briese T & Hakenbeck R (1985) Interaction of the pneumococcal amidase with lipoteichoic acid and choline. Eur. J. Biochem. 146: 417–427CrossRefPubMedGoogle Scholar
  62. Briles DE, Nahm M, Schroer K, Davie J, Baker P, Kearney J & Barletta P (1981a) Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3Streptococcus pneumoniae. J. Exp. Med. 153: 694–705CrossRefPubMedGoogle Scholar
  63. Briles DE, Claflin JL, Schroer K & Forman C (1981b) Mouse IgG3 antibodies are highly protective against infection withStreptococcus pneumoniae. Nature 294: 88–90CrossRefPubMedGoogle Scholar
  64. Briles DE, Forman C, Horowitz JC, Volanakis JE, Benjamin WH, McDaniel LS, Eldridge J & Brooks J (1989) Antipneumococcal effects of C-Reactive Protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens. Infect. Immun. 57: 1457–1464PubMedGoogle Scholar
  65. Brooke MS (1964) Breaking of immunological paralysis by injection of a specific depolymerase. Nature 204: 1319–1320PubMedGoogle Scholar
  66. Brown AE, Quesada O, Jackson M, Armstrong D, Arlin Z, Gee T, Clarkson B & Schiffman G (1982a) Pneumococcal immunization in patients with myelogenous leukemia before and after splenectomy. Clin. Res. 30: 696AGoogle Scholar
  67. Brown EJ, Hosea SW, Hammer CH, Burch CG & Frank MM (1982b) A quantitative analysis of the interactions of antipneumococcal antibody and complement in experimental pneumococcal bacteremia. J. Clin. Invest. 69: 85–98PubMedGoogle Scholar
  68. Brown EJ, Hosea SW & Frank MM (1983a) The role of antibody and complement in the reticuloendothelial clearance of pneumococci from the bloodstream. Rev. Infect. Dis. 5: S797-S805PubMedGoogle Scholar
  69. Brown EJ, Joiner KA, Cole RM & Berger M (1983b) Localization of complement component 3 onStreptococcus pneumoniae: anti-capsular antibody causes complement deposition on the pneumococcal capsule. Infect. Immun. 39: 403–409PubMedGoogle Scholar
  70. Brown EJ, Joiner KA, Gaiter TA, Hammer CH & Frank MM (1983c) The interaction of C3b bound to pneumococci with factor H (β1H globulin), factor I (C3b/C4b inactivator), and properdin factor B of the human complement system. J. Immunol 131: 409–415PubMedGoogle Scholar
  71. Buchanan GR & Smith SJ (1986) Pneumococcal septicemia despite pneumococcal vaccine and prescription of penicillin prophylaxis in children with sickle cell anemia. Amer. J. Dis. Child. 140: 428–432PubMedGoogle Scholar
  72. Bukantz SC, DeGara PF & Bullowa JGM (1942) Capsular polysaccharides in blood in pneumococcal pneumonia. Arch. Intern. Med. 69: 191–212Google Scholar
  73. Burman LÅ, Norrby R & Trollfors B (1985) Invasive pneumococcal infections: incidence, predisposing factors, and prognosis. Rev. Infect. Dis. 7: 133–142PubMedGoogle Scholar
  74. Busby BET & Roberson BS (1981) Phytohemagglutinin-induced enhancement and IgG subclass restriction of the immune response to type III pneumococcal polysaccharide. Cell. Immunol. 65: 280–292CrossRefGoogle Scholar
  75. Campbell JH & Pappenheimer AM (1966) Quantitative studies of the specificity of anti-pneumococcal polysaccharide antibodies types III and VIII -1. Isolation of oligosaccharides from acid and from enzymatic hydrolysates of S3 and S8. -2. Inhibition of precipitin reactions with oligosaccharides isolated from hydrolysates of S3 and S8. Immunochemistry 3: 195–212; 213–222PubMedGoogle Scholar
  76. Caroff M & Perry MB (1984) The specific capsular polysaccharide ofStreptococcus pneumoniae type 15A (American type 30). Can. J. Biochem. Cell Biol. 62: 151–161PubMedGoogle Scholar
  77. Centers for Disease Control, Dept. Hlth & Human Serv., Atlanta, Georgia (1984) Update: Pneumococcal polysaccharide vaccine usage — United States. Ann. Intern. Med. 101: 348–350Google Scholar
  78. Centers for Disease Control, Dept. Hlth & Human Serv., Atlanta, Georgia (1989) Recommendations of the Immunization Practices Advisory Committee Pneumococcal Polysaccharide vaccine. J. Amer. Med. Assoc. 261: 1265–1267Google Scholar
  79. Chernyak AYa, Antonov KV, Kochetkov NK, Padyukov LN & Tsvetkova NV (1985) Two synthetic antigens related toStreptococcus pneumoniae type 3 capsular polysaccharide. Carbohydr. Res. 141: 199–212CrossRefPubMedGoogle Scholar
  80. Cheson BD, Walker HS, Heath ME, Gobel RJ & Janatova J (1984) Defective binding of the third component of complement (C3) toStreptococcus pneumoniae in multiple myeloma. Blood 63: 949–957PubMedGoogle Scholar
  81. Chetty C & Kreger A (1985) Generation of purpura-producing principle from pneumococcal cell walls. J. Bacteriol. 163: 389–391PubMedGoogle Scholar
  82. Chittenden GJF, Roberts WK, Buchanan JG & Baddiley J (1968) The specific substance from pneumococcus type 34 (41). Biochem. J. 109: 597–602PubMedGoogle Scholar
  83. Christensen KK, Christensen P, Faxelius G, Henrichsen J & Pedersen FK (1985a) Immune response to pneumococcal vaccine in mothers to infants with group B streptococcal septicemia: evidence for a divergent IgG/IgM ratio. Int. Arch. Allergy Appl. Immunol. 76: 369–372PubMedGoogle Scholar
  84. Christensen P, Hovelius B, Prellner K, Rosén C, Christensen KK, Kurl DN, Larsson L, Stjernquist-Desatnik A & Schalén C (1985b) Effects of pneumococcal vaccination on tonsilopharingitis and upper respiratory tract flora. Int. Arch. Allergy Appl. Immunol. 78: 161–166PubMedGoogle Scholar
  85. Chudwin DS, Artrip SG, Korenblit A, Schiffman G & Rao S (1985a) Correlation of serum opsonins with in vitro phagocytosis ofStreptococcus pneumoniae. Infect. Immun. 50: 213–217PubMedGoogle Scholar
  86. Chudwin DS, Wara DW, Schiffman G, Artrip SG & Ammann AJ (1985b) Maternal-fetal transfer of pneumococcal capsular polysaccharide antibodies. Amer. J. Dis. Child. 139: 378–380PubMedGoogle Scholar
  87. Chudwin DS, Artrip SG & Schiffman G (1987) Immunoglobulin G class and subclass antibodies to pneumococcal capsular polysaccharides. Clin. Immunol. Immunopathol. 44: 114–121CrossRefPubMedGoogle Scholar
  88. Chudwin DS (1989) Prophylaxis and treatment of pneumococcal bacteremia by Immune Globulin Intravenous in a mouse model. Clin. Immunol. Immunopathol. 50: 62–71CrossRefPubMedGoogle Scholar
  89. Cohn DA & Schiffman G (1987) Immunoregulatory role of the spleen in antibody responses to pneumococcal polysaccharide antigens. Infect. Immun. 55: 1375–1380PubMedGoogle Scholar
  90. Colling RG, Pearson TC & Brown JC (1983) Association of bacterial carbohydrate-specific cold agglutinin antibody production with immunization by group C, group B type III, andStreptotoccus pneumoniae type XIV streptococcal vaccines. Infect. Immun. 41: 205–213PubMedGoogle Scholar
  91. Coonrod JD & Yoneda K (1982) Comparative role of complement in pneumococcal and staphylococcal pneumonia. Infect. Immun. 37: 1270–1277PubMedGoogle Scholar
  92. Coonrod JD, Marple S, Holmes GP & Rehm SR (1987a) Extracellular killing of inhaled pneumococci in rats. J. Lab. Clin. Med. 110: 753–766PubMedGoogle Scholar
  93. Coonrod JD, Jarrells MC & Bridges RB (1987b) Impaired pulmonar clearance of pneumococci in neonatal rats. Pedriatr. Res. 22: 736–742Google Scholar
  94. Das A, Heidelberger M & Brown R (1976) Identification of D-galacturonic acid in the specific capsular polysaccharide of pneumococcal type XXV. Carbohydr. Res. 48: 304–305CrossRefPubMedGoogle Scholar
  95. DeLisi C & Berzofsky JA (1985) T-cell antigenic sites tend to be amphipatic structures. Proc. Natl. Acad. Sci. USA 82: 7048–7052PubMedGoogle Scholar
  96. Denis FA, Greenwood BD, Rey JL, Prince-David M, Mboub S, Lloyd-Evans N, Williams K, Bennachir I, El Ndaghri N, Hansman D, Omanga V, Krubwa K, Duchassin M & Perrin J (1983) Étude multicentrique des sérotypes des pneumocoques en Afrique. Bull. W. H. O. 61: 661–669PubMedGoogle Scholar
  97. Diena BB, Ashton FE & Perry MB (1979) Type-14 pneumococcal vaccine for prevention of gonorrhoeae. Lancet 1: 1037PubMedGoogle Scholar
  98. DiPadova F, Dürig M, Harder F, DiPadova C & Zanussi C (1985) Impaired antipneumococcal antibody production in patients without spleens. Brit. Med. J. 290: 14–16Google Scholar
  99. Dixon JMS & Lipinsky AE (1981) Pneumococcal serotypes causing bacteremia and meningitis: relevance to composition of pneumococcal vaccine. Can. Med. Assoc. 125: 263–267Google Scholar
  100. Donaldson SS, Vosti KL, Berberich FR, Cox RS, Kaplan HS & Schiffman G (1981) Response to pneumococcal vaccine among children with Hodgkin's disease. Rev. Infect. Dis. 3: S133–143PubMedGoogle Scholar
  101. Douglas RM, Paton JC, Duncan SJ & Hansman DJ (1983) Antibody response to pneumococcal vaccination in children younger than five years of age. J. Infect. Dis. 148: 131–137PubMedGoogle Scholar
  102. Douglas RM, Hansman D, Miles HB & Paton JC (1986) Pneumococcal carriage and type specific antibody. Failure of a 14-valent vaccine to reduce carriage in healthy children. J. Dis. Child. 140: 1183–1185Google Scholar
  103. Drew PA, Nieuwhof WN, Clarkson AR & Woodroffe AJ (1987) Increased concentration of serum IgA antibody to pneumococcal polysaccharides in patients with IgA nephropathy. Clin. Exp. Immunol. 67: 1124–1129Google Scholar
  104. Dubos R & Avery OT (1931) Decomposition of the capsular polysaccharide of pneumococcus type III by a bacterial enzyme. J. Exp. Med. 54: 51–71CrossRefGoogle Scholar
  105. Edwards KM, Gewurz H, Lint TF & Mold C (1982) A role for C-reactive protein in the complement-mediated stimulation of human neutrophils by type 27Streptococcus pneumoniae. J. Immunol. 128: 2493–2496PubMedGoogle Scholar
  106. Eskola J, Peltola H, Takala AK, Käyhty H, Hakulinen M, Karanko V, Kela E, Rekola P, Rönnberg P-R, Samuelson JS, Gordon LK & Mäkelä PH (1987) Efficacy ofHaemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine. N. Engl. J. Med. 317: 717–722PubMedGoogle Scholar
  107. Estrada-Parra S & Heidelberger M (1963) The specific polysaccharide of type XVIII pneumococcus. Biochemistry 2: 1288–1294CrossRefPubMedGoogle Scholar
  108. Fairchild RL, Sterner KE & Braley-Mullen H (1986) Primary murine immunoglobulin M response to certain pneumococcal capsular polysaccharides consists primarily of anti-pneumococcal cell wall carbohydrate antibodies. Infect. Immun. 52: 867–871PubMedGoogle Scholar
  109. Fattom A, Vann WF, Szu SC, Sutton A, Li X, Brylan D, Schiffman G, Robbins JB & Schneerson R (1988) Synthesis and physicochemical and immunological characterization of pneumococcus type 12F polysaccharide-diphtheria toxoid conjugates. Infect. Immun. 56: 2292–2298PubMedGoogle Scholar
  110. Fine DP (1975) Pneumococcal type-associated variability in alternate complement pathway activation. Infect. Immun. 12: 772–778PubMedGoogle Scholar
  111. Fine DP, Kirk JL, Schiffman G, Schweinle JE & Guckian JC (1988) Analysis of humoral and phagocytic defenses againstStreptococcus pneumoniae serotypes 1 and 3. J. Lab. Clin. Med. 112: 487–497PubMedGoogle Scholar
  112. Finland M & Barnes MW (1977) Changes in occurrence of capsular serotypes ofStreptococcus pneumoniae at Boston City Hospital during selected years between 1935 and 1974. J. Clin. Microbiol. 5: 154–166PubMedGoogle Scholar
  113. Fischer GW, Lowell GH, Crumrine MH & Bass JW (1978) Demonstration of opsonic activity and in vivo protection against group B streptococci type III byStreptococcus pneumoniae type 14 antisera. J. Exp. Med. 148: 776–786CrossRefPubMedGoogle Scholar
  114. Fischer GW, Lowell GH, Crumrine MH & Wilson SR (1979) Immunoprecipitation and opsonic cross-reaction between type 14 pneumococcus and group B streptococcus type III. Lancet 1: 75–77PubMedGoogle Scholar
  115. Fischer H & Tomasz A (1985) Peptidoglycan cross-linking and teichoic acid attachment inStreptococcus pneumoniae. J. Bacteriol. 163: 46–54PubMedGoogle Scholar
  116. Fujiwara M (1967) The Forssman antigen of pneumococcus. Jap. J. Exp. Med. 37: 581–592PubMedGoogle Scholar
  117. Fukuda NM (1985) Isolation and characterization of a new endo-β-galactosidase fromDiplococcus pneumoniae. Biochemistry 24: 2154–2163CrossRefPubMedGoogle Scholar
  118. Gahan LC, Sandford PA & Conrad HE (1967) Structure of the serotype 2 capsular polysaccharide ofAerobacter aerogenes. Biochemistry 6: 2755–2766CrossRefPubMedGoogle Scholar
  119. Galili U, Macher BA, Buehler J & Shohet SB (1985) Human natural anti-α-galactosyl IgG. II. The specific recognition of α(1 → 3)-linked galactose residues. J. Exp. Med. 162: 573–582CrossRefPubMedGoogle Scholar
  120. Garcia-Bustos JF, Chait BT & Tomasz A (1987) Structure of the peptide network of pneumococcal peptidoglycan. J. Biol. Chem. 262: 15400–15405PubMedGoogle Scholar
  121. Garcia-Bustos JF, Chait BT & Tomasz A (1988) Altered peptidoglycan structure in a pneumococcal transformant resistant to penicillin. J. Bacteriol. 170: 2143–2147PubMedGoogle Scholar
  122. Gardner SE, Anderson DC, Webb BJ, Stitzel AE, Edwards MS, Spitzer RE & Baker CJ (1982) Evaluation ofStreptococcus pneumoniae type XIV opsonins by phagocytosis-associated chemiluminiscence and a bactericidal assay. Infect. Immun. 35: 800–808PubMedGoogle Scholar
  123. Giebink GS, Verhoef J, Peterson PK & Quie PG (1977) Opsonic requirements for phagocytosis ofStreptococcus pneumoniae types VI, XVIII, XXIII, and XXV. Infect. Immun. 18: 291–295PubMedGoogle Scholar
  124. Giebink GS, Le CT & Schiffman G (1984) Decline of serum antibody in splenectomized children after vaccination with pneumococcal capsular polysaccharides. J. Pediatr. 105: 576–582PubMedGoogle Scholar
  125. Giebink GS, Warkentin PI, Ramsay NKC & Kersey JH (1986) Titers of antibody to pneumococci in allogeneic bone marrow transplant recipients before and after vaccination with pneumococcal vaccine. J. Infect. Dis. 154: 590–596PubMedGoogle Scholar
  126. Giudicelli S & Tomasz A (1984) Attachment of pneumococcal autolysin to wall teichoic acids, an essential step in enzymatic wall degradation. J. Bacteriol. 158: 1188–1190PubMedGoogle Scholar
  127. Goebel WF (1939) Studies on antibacterial immunity induced by artificial antigens. I. Immunity to experimental pneumococcal infection with an antigen containing cellobiuronic acid. J. Exp. Med. 69: 353–364CrossRefGoogle Scholar
  128. Goldblum SE, Reed WP & Thilsted JP (1983) Pneumococcal sonicate-induced biphasic granulocytopenia and its dissociation from pulmonary leukostasis. J. Lab. Clin. Med. 102: 987–999PubMedGoogle Scholar
  129. Gonzaga RA (1984) Fatal post-splenectomy pneumococcal sepsis despite prophylaxis. Lancet 2: 694–695PubMedGoogle Scholar
  130. Goodman JW & Kabat EA (1960) Immunochemical studies on cross-reactions of antipneumococcal sera. -2. Cross-reactions of types IX and XII antipneumococcal sera with dextrans. J. Immunol. 84: 347–357PubMedGoogle Scholar
  131. Gordon DL, Johnson GM & Hostetter MK (1986) Ligand-receptor interactions in the phagocytosis of virulentStreptococcus pneumoniae by polymorphonuclear leukocytes. J. Infect. Dis. 154: 619–626PubMedGoogle Scholar
  132. Gransden WR & Eykyn SJ (1988) Empyema in pneumococcal bacteremia. Rev. Infect. Dis. 10: 1227–1228PubMedGoogle Scholar
  133. Gray BM, Turner ME & Dillon HC (1982) Epidemiologic studies ofStreptococcus pneumoniae in infants: The effects of season and age on pneumococcal acquisition and carriage in the first 24 months of life. Amer. J. Epidemiol. 116: 692–703Google Scholar
  134. Gray BM, Dillon HC & Briles DE (1983) Epidemiological studies ofStreptococcus pneumoniae in infants: development of antibody to phosphocholine. J. Clin. Microbiol. 18: 1102–1107PubMedGoogle Scholar
  135. Gray BM & Dillon HC (1988) Epidemiological studies ofStreptococcus pneumoniae in infants: antibody to types 3, 6, 14, and 23 in the first two years of life. J. Infect. Dis. 158: 948–955PubMedGoogle Scholar
  136. Griffiss JMcL & Goroff DK (1983) IgA blocks IgM and IgG-initiated immune lysis by separate molecular mechanisms. J. Immunol. 130: 2882–2885PubMedGoogle Scholar
  137. Griffiss JMcL, Apicella MA, Greenwood B & Mäkelä PH (1987) Vaccines against encapsulated bacteria: a global agenda. Rev. Infect. Dis. 9: 176–188PubMedGoogle Scholar
  138. Grover GJ & Loegering DJ (1984) Role of the liver in host defense to pneumococcus following splenectomy. J. Surg. Res. 37: 448–452CrossRefPubMedGoogle Scholar
  139. Gruer LD, McKendrick MW & Geddes AM (1984) Pneumococcal bacteremia — a continuing challenge. Quart. J. Med. 210: 259–270Google Scholar
  140. Guillet J-G, Lai M-Z, Briner TJ, Buus S, Sette A, Grey HM, Smith JA, Gefter ML (1987) Immunological self, non-self discrimination. Science 235: 865–870PubMedGoogle Scholar
  141. Hammarström L & Smith CIE (1986) Development of antipolysaccharide antibodies in asplenic children. Clin. Exp. Immunol. 66: 457–462PubMedGoogle Scholar
  142. Hebert JC (1989) Pneumococcal vaccine improves pulmonary clearance of live pneumococci after splenectomy. J. Surg. Res. 47: 283–287CrossRefPubMedGoogle Scholar
  143. Heidelberger M (1960) Structure and immunological specificity of polysaccharides. Fortschr. Chem. Org. Naturstoffe 18: 503–536Google Scholar
  144. Heidelberger M (1962) Immunochemistry of pneumococcal types II, V, and VI. 4. Cross-reactions of type V antipneumococcal sera and their bearing on the relation between type II and V. Arch. Biochem. Biophys. Suppl. 1: 169–173Google Scholar
  145. Heidelberger M (1983) Precipitating cross-reactions among pneumococcal types. Infect. Immun. 41: 1234–1244PubMedGoogle Scholar
  146. Heidelberger M & Kendall FE (1933) Studies on the precipitin reaction. Precipitating haptens: species differences in antibodies. J. Exp. Med. 57: 373–379CrossRefGoogle Scholar
  147. Heidelberger M & Rebers PA (1960) Immunochemistry of the pneumococcal types II, V, and VI. 1. The relation of type VI to type II and other correlations between chemical constitution and precipitation in antisera to type VI. J. Bacteriol. 80: 145–153PubMedGoogle Scholar
  148. Heidelberger M, Dudman WF & Nimmich W (1970) Immunochemical relationships of certain capsular polysaccharides ofKlebsiella, pneumococci andRhizobia. J. Immunol. 104: 1321–1328PubMedGoogle Scholar
  149. Heidelberger M & Nimmich W (1976) Immunochemical relationships between bacteria belonging to two separate families; pneumococci andKlebsiella. Immunochemistry 13: 67–80CrossRefPubMedGoogle Scholar
  150. Heilmann C (1987) Vaccination-induced activation of human blood T cells suppressing pneumococcal polysaccharide-specific B cells. Acta Pathol. Immunol. Scand. C 95: 65–69Google Scholar
  151. Heilmann C & Pedersen FK (1986) Quantitation of blood lymphocytes secreting antibodies to pneumococcal polysaccharides after in vivo antigenic stimulation. Scand. J. Immunol. 23: 189–194PubMedGoogle Scholar
  152. Heilmann C, Henrichsen J & Pedersen FK (1987) Vaccination-induced circulation of human B cells secreting type-specific antibodies against pneumococcal polysaccharides. Scand. J. Immunol. 25: 61–67PubMedGoogle Scholar
  153. Heilmann C, Barington T & Sigsgaard T (1988) Subclass of individual IgA-secreting human lymphocytes. Investigation of in vivo pneumococcal polysaccharide-induced and in vitro mitogen-induced blood B cells by monolayer plaque-forming cell assays. J. Immunol. 140: 1496–1499PubMedGoogle Scholar
  154. Heilmann C & Barington T (1989) Distribution of ϰ and λ light chain isotypes among human blood immunoglobulin-secreting cells after vaccination with pneumococcal polysaccharides. Scand. J. Immunol. 29: 159–164PubMedGoogle Scholar
  155. Higginbotham JD, Heidelberger M & Gotschlich E (1970) Degradation of a pneumococcal type-specific polysaccharide with exposure of group-specificity. Proc. Natl. Acad. Sci. USA 67: 138–142PubMedGoogle Scholar
  156. Höltje JV & Tomasz A (1975) Lipoteichoic acid: a specific inhibitor of autolysin activity in pneumococcus. Proc. Natl. Acad. Sci. USA 72: 1690–1694PubMedGoogle Scholar
  157. Holowka DA, Strosberg AD, Kimball JW, Haber E & Cathou RE (1972) Changes in intrinsic circular dichroism of several homogenous anti-type III pneumococcal antibodies on binding of a small hapten. Proc. Nat. Acad. Sci. USA 69: 3399–3403PubMedGoogle Scholar
  158. Holzer TJ, Edwards KM, Gewurz H & Mold C (1984) Binding of C-reactive protein to the pneumococcal capsule or cell wall results in differential localization of C3 and stimulation of phagocytosis. J. Immunol. 133: 1424–1430PubMedGoogle Scholar
  159. Horne D & Tomasz A (1985) Pneumococcal Forssman antigen: enrichment in mesosomal membranes and specific binding to the autolytic enzyme ofStreptococcus pneumoniae. J. Bacteriol. 161: 18–24PubMedGoogle Scholar
  160. Horohito S, Lorentzen JP & Paulsen H (1986) Synthese einer Trisaccharideinheit des Kapselpolysaccharides vonStreptococcus pneumoniae Typ 4. Lieb. Ann. Chem. 1880–1890Google Scholar
  161. Horowitz J, Volanakis JE & Briles DE (1987) Blood clearance ofStreptococcus pneumoniae by C-reactive protein. J. Immunol. 138: 2598–2603PubMedGoogle Scholar
  162. Hosea SW (1983) Role of the spleen in pneumococcal infection. Lymphology 16: 115–120PubMedGoogle Scholar
  163. Hosea SW, Brown EJ, Hamburger MI & Frank MM (1981a) Opsonic requirements for intravascular clearance after splenectomy. N. Engl. J. Med. 304: 245–250PubMedGoogle Scholar
  164. Hosea SW, Burch CG, Brown EJ, Berg RA & Frank MM (1981b) Impaired immune response of splenectomized patients to polyvalent pneumococcal vaccine. Lancet 1: 804–807PubMedGoogle Scholar
  165. Hostetter MK (1986) Serotypic variations among virulent pneumococci in deposition and degradation of covalently bound C3b: implications for phagocytosis and antibody production. J. Infect. Dis. 153: 682–693PubMedGoogle Scholar
  166. Howard JG, Zola H, Christie GH & Courtenay BM (1971) Studies on immunological paralysis: V. The influence of molecular weight on the immunogenicity, tolerogenicity and antibody-neutralizing activity of type III pneumococcal polysaccharide. Immunology 21: 535–546PubMedGoogle Scholar
  167. Huang K-L, Ruben FL, Rinaldo CR, Kingsley LR, Lyter DW & Ho M (1987) Antibody responses after influenza and pneumococcal immunization in HIV-infected homosexual men. J. Amer. Med. Assoc. 257: 2047–2050CrossRefGoogle Scholar
  168. Hummell DS, Swift AJ, Tomasz A & Winkelstein JA (1985) Activation of the alternative complement pathway by pneumococcal lipoteichoic acid. Infect. Immun. 47: 384–387PubMedGoogle Scholar
  169. Hummell DS, Berninger RW & Tomasz A (1981) The fixation of C3b to pneumococcal cell wall polymers as a result of activation of the alternative complement pathway. J. Immunol. 127: 1287–1289PubMedGoogle Scholar
  170. Iinuma H & Okinaga K (1989) Prevention of pneumococcal bacteremia by immunization with type 6 pneumococcal capsular polysaccharide vaccine in splenectomized rats. J. Infect. Dis. 160: 66–75PubMedGoogle Scholar
  171. Insell RA & Anderson PW (1986) Response to oligosaccharide-protein conjugates vaccine againstH. influenzae b in two patients with IgG2 deficiency unresponsive to capsular polysaccharide vaccine. N. Engl. J. Med. 315: 499–503Google Scholar
  172. Jacquot J, Pluchelle E, Zahm JM, Beck G & Plotkowski MC (1987) Effect of human lysozyme on the in vitro growth of type IStreptococcus pneumoniae. Eur. J. Respir. Dis. 71: 295–305PubMedGoogle Scholar
  173. Janoff EN, Douglas JM, Gabriel M, Blaser MJ, Davidson AJ, Cohn DL & Judson FN (1988) Class-specific antibody response to pneumococcal capsular polysaccharides in men infected with human immunodeficiency virus type 1. J. Infect. Dis. 158: 983–990PubMedGoogle Scholar
  174. Jansson P-E, Lindberg B, Lindquist U & Carlo DJ (1983) Structural studies of the capsular polysaccharide fromStreptococcus pneumoniae type 17A. Carbohydr. Res. 118: 157–171CrossRefGoogle Scholar
  175. Jansson P-E, Lindberg B & Lindquist U (1985) Structural studies of the capsular polysaccharide fromStreptococcus pneumoniae type 5. Carbohydr. Res. 140: 101–110CrossRefPubMedGoogle Scholar
  176. Jansson P-E, Lindberg B, Lindquist U & Ljungberg J (1987) Structural studies of the capsular polysaccharide fromStreptococcus pneumoniae types 15B and 15C. Carbohydr. Res. 162: 111–116CrossRefPubMedGoogle Scholar
  177. Jansson P-E, Lindberg B, Lindberg J & Henrichsen J (1988a) Structural studies of the capsular polysaccharide fromStreptococcus pneumoniae type 18F. Carbohydr. Res. 173: 217–225PubMedGoogle Scholar
  178. Jansson P-E, Kumar NS, Lindberg B, Widmalm G & Henrichsen J (1988b) Structural studies of the capsular polysaccharide fromStreptococcus pneumoniae type 18A. Carbohydr. Res. 173: 227–233PubMedGoogle Scholar
  179. Jansson P-E, Lindberg B, Andersson M, Lindquist U & Henrichsen J (1988c) Structural studies of the capsular polysaccharide fromStreptococcus pneumoniae type 2, a reinvestigation. Carbohydr. Res. 182: 111–117PubMedGoogle Scholar
  180. Jansson P-E, Lindberg B & Lindquist U (1988d) Structure of the capsular polysaccharide fromStreptococcus pneumoniae type 7A. Abstr. XIVth Int. Carbohydr. Symp., Stockholm, p 152Google Scholar
  181. Jennings HJ, Lugoswki C & Young NM (1980a) Structure of the complex polysaccharide C-substance fromStreptococcus pneumoniae type 1. Biochemistry 19: 4712–4719CrossRefPubMedGoogle Scholar
  182. Jennings HJ, Rosell K-G & Kasper DL (1980b) Structural determination and serology of the native polysaccharide antigen of type III group BStreptococcus. Can. J. Biochem. 58: 112–120PubMedGoogle Scholar
  183. Jennings HJ, Roy R & Gamian A (1986) Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice using anN-propionylated B-polysaccharide-tetanus toxoid conjugated vaccine. J. Immunol. 137: 1708–1713PubMedGoogle Scholar
  184. Jennings HJ, Gamian A & Ashton FE (1987)N-propionylated group B meningococcal polysaccharide mimmics a unique epitope on group BNeisseria meningitidis. J. Exp. Med. 165: 1207–1211CrossRefPubMedGoogle Scholar
  185. Jerne NK, Roland J & Cazenave P-A (1982) Recurrent idiotopes and internal images. EMBO J. 1: 243–247PubMedGoogle Scholar
  186. John AB, Ramlal A, Jackson H, Maude GH, Sharma AW & Serjeant GR (1984) Prevention of pneumococcal infection in children with homozygous sickle cell disease. Brit. Med. J. 288: 1567–1570Google Scholar
  187. Joiner K, Brown E, Hammer C, Warren K & Frank M (1983) Studies on the mechanism of bacterial resistance to complement-mediated killing. III. C5b-9 deposits stably on rough and type 7S. pneumoniae without causing bacterial killing. J. Immunol. 130: 845–849PubMedGoogle Scholar
  188. Jones C, Mulloy B, Wilson A, Dell A & Oates JE (1985) Structure of the capsular polysaccharide fromStreptococcus pneumoniae type 9. J. Chem. Soc. Perkin I: 1665–1673Google Scholar
  189. Jones C & Currie F (1988) The pneumococcal polysaccharide S4: a structural re-assessment. Carbohydr. Res. 184: 279–284CrossRefPubMedGoogle Scholar
  190. Jones JNK & Perry MB (1957) The structure of the type VIII pneumococcus specific polysaccharide. J. Amer. Chem. Soc. 79: 2787–2793Google Scholar
  191. Kabat EA (1962) Immunochemical studies on bloodgroups. -29. Action of various oligosaccharides from human milk in inhibiting the cross-reactions of type XIV antipneumococcal sera with partially hydrolyzed blood group substances (P1 fractions). Arch. Biochem. Biophys. Suppl. 1: 181–186Google Scholar
  192. Kabat EA, Liao J & Lemieux RU (1978) Immunochemical studies of blood groups. -68. The combining site of anti-I Ma (group 1). Immunochemistry 15: 727–731PubMedGoogle Scholar
  193. Kalm O, Prellner K & Pedersen FK (1984) Pneumococcal antibodies in families with recurrent otitis media. Int. Arch. Allergy Appl. Immunol. 75: 139–142PubMedGoogle Scholar
  194. Kalm O, Prellner K, Freijd A & Rynnel-Dagöö B (1986) Antibody activity before and after pneumococcal vaccination of otitis-prone and non-otitis-prone children. Acta Otolaryngol. 101: 467–474PubMedGoogle Scholar
  195. Karma P, Pukander J, Sipilä M & Mäkelä PH (1982) Recurrent otitis media in children after pneumococcal vaccination. Acta Otolaryngol. Suppl. 386: 117–120Google Scholar
  196. Kasper DL, Goroff DK & Baker CJ (1978) Immunochemical characterization of native polysaccharides from group BStreptococcus: the relationship of the type III and group B determinants. J. Immunol. 121: 1096–1105PubMedGoogle Scholar
  197. Katz M & Pappenheimer AM (1969) Quantitative studies of the specificity of anti-pneumococcal antibodies, type III and VIII -4. Binding of labeled hexasaccharides derived from S3 by anti-S3 antibodies and their Fab fragments. J. Immunol. 103: 491–495PubMedGoogle Scholar
  198. Katzenellenbogen E & Jennings HJ (1983) Structural determination of the capsular polysaccharide ofStreptococcus pneumoniae type 19A (57). Carbohydr. Res. 124: 235–245CrossRefPubMedGoogle Scholar
  199. Kaufmann F, Lund E & Eddy BE (1960) Proposal for a change in the nomenclature ofDiplococcus pneumoniae and a comparison of the Danish and American type designations. Int. Bull. Bacteriol. Taxon. 10: 31–40Google Scholar
  200. Kearney R (1983) Binding of murine IgM and monoclonal IgM/A(κ) hybrid anti-type III pneumococcal polysaccharide (SIII) antibodies to Staphylococcal protein A. Aust. J. Exp. Biol. Med. Sci. 61: 91–104PubMedGoogle Scholar
  201. Kearney R & Johnstone S (1985) Regulation of immunity and tolerance to type III pneumococcal polysaccharide (SIII) by functionally distinct IgM anti-SIII antibodies. Aust. J. Exp. Biol. Med. Sci. 63: 19–32PubMedGoogle Scholar
  202. Kearney R, Andrews J & Johnstone S (1986) The role of a functionally distinct IgM anti-type III pneumococcal polysaccharide (SIII) in low-dose paralysis to SIII in mice. Aust. J. Exp. Biol. Med. Sci. 64: 19–35PubMedGoogle Scholar
  203. Kehrl JH & Fauci AS (1983a) Characterization of the cellular immune response following in vivo immunization with pneumococcal polysaccharides in man. Bull. Eur. Physiopath. Resp. 19: 227–234Google Scholar
  204. Kehrl JH & Fauci AS (1983b) Activation of human B lymphocytes after immunization with pneumococcal polysaccharides. J. Clin. Invest. 71: 1032–1040PubMedGoogle Scholar
  205. Kehrl JH & Fauci AS (1983c) Identification, purification, and characterization of antigen-activated and antigen-specific human B lymphocytes. J. Exp. Med. 157: 1692–1697CrossRefPubMedGoogle Scholar
  206. Kenne L, Lindberg B & Madden JK (1979) Structural studies of the capsular antigen fromStreptococcus pneumoniae type 26. Carbohydr. Res. 73: 175–182CrossRefPubMedGoogle Scholar
  207. Kenne L & Lindberg B (1988) The structure ofStreptococcus pneumoniae type 29 polysaccharide: a re-examination. Carbohydr. Res. 184: 288–291CrossRefPubMedGoogle Scholar
  208. Kennedy DA, Buchanan JG & Baddiley J (1969) The type specific substance from pneumococcus type 11A (43). Biochem. J. 115: 37–45PubMedGoogle Scholar
  209. Khater M, Macai J, Genyea C & Kaplan J (1986) Natural killer cell regulation of age-related and type-specific variations in antibody responses to pneumococcal polysaccharides. J. Exp. Med. 164: 1505–1515CrossRefPubMedGoogle Scholar
  210. Kilian M, Mestecky J, Kulhavy R, Tomana M & Butler WT (1980) IgA1 proteases fromHaemophilus influenzae, Streptococcus pneumoniae, Neisseria meningitidis andStreptococcus sanguis: comparative immunochemical studies. J. Immunol. 124: 2596–2600PubMedGoogle Scholar
  211. Kochetkov NK, Nifant'ev NE & Backinowsky LV (1987) Synthesis of the capsular polysaccharide ofStreptococcus pneumoniae type 14. Tetrahedron 43: 3109–3121Google Scholar
  212. Kornfeld SJ & Plaut AG (1981) Secretory immunity and bacterial IgA proteases. Rev. Infect. Dis. 3: 521–534PubMedGoogle Scholar
  213. Koskela M, Leinonen M, Häivä V-M, Timonen M & Mäkelä PH (1986) First and second dose antibody responses to pneumoncoccal polysaccharide vaccine in infants. Pediatr. Infect. Dis. 5: 45–50PubMedGoogle Scholar
  214. Kraus C, Fischer S, Ansorg R & Hüttemann U (1985) Pneumococcal antibodies (IgG, IgM) in patients with chronic obstructive lung disease 3 years after pneumococcal vaccination. Med. Microbiol. Immunol. 174: 51–58CrossRefPubMedGoogle Scholar
  215. Lagergård T & Branefors P (1983) Nature of cross-reactivity betweenHaemophilus influenzae types a and b andStreptococcus pneumoniae types 6A and 6B. Acta Path. Microbiol. Immunol. Scand. C 91: 371–376Google Scholar
  216. Lai E, Kabat EA & Mobraaten L (1985) Genetic and nongenetic control of the immune response of mice to a synthetic glycolipid, stearylisomaltotetraose. Cellul. Immunol. 92: 172–183Google Scholar
  217. Landesman SH & Schiffman G (1981) Assessment of the antibody response to pneumococcal vaccine in high-risk populations. Rev. Infect. Dis. 3 (1981) S184–197PubMedGoogle Scholar
  218. Lane PJL & MacLennan ICM (1986) Impaired IgG2 anti-pneumococcal antibody responses in patients with recurrent infection and normal IgG2 levels but no IgA. Clin. Exp. Immunol. 65: 427–433PubMedGoogle Scholar
  219. Lazarus HM, Lederman M, Lubin A, Herzig R, Schiffman G, Jones P, Wine A & Rodman HM (1980) Pneumococcal vaccination: the response of patients with multiple myeloma. Amer. J. Med. 96: 419–423Google Scholar
  220. Lee C-J & Fraser BA (1980) The structures of the cross-reactive types 19 (19F) and 57 (19A) pneumococcal polysaccharides. J. Biol. Chem. 255: 6847–6853PubMedGoogle Scholar
  221. Lee C-J, Fraser BA, Szu S & Lin K-T (1981) Chemical structure of and immune response to polysaccharides ofStreptococcus pneumoniae. Rev. Infect. Dis. 3: 323–331PubMedGoogle Scholar
  222. Lee C-J & Wang Z (1985) Induction of increased antibody responses to pneumococcal type 19F polysaccharide byKlebsiella polysaccharide. J. Infect. Dis. 151: 658–664PubMedGoogle Scholar
  223. Lee C-J, Fraser BA, Boykins RA & Li JP (1987a) Effect of culture conditions on the structure ofStreptococcus pneumoniae type 19A (57) capsular polysaccharide. Infect. Immun. 55: 1819–1823PubMedGoogle Scholar
  224. Lee C-J, Takaoka Y & Saito T (1987b) Maternal immunization and the immune response of neonates to pneumococcal polysaccharides. Rev. Infect. Dis. 9: 494–510PubMedGoogle Scholar
  225. Lee DA, Hoidal JR, Garlich DH, Clawson CC, Quie PG & Peterson PK (1984) Opsonin-independent phagocytosis of surface-adherent bacteria by human alveolar macrophages. J. Leukocyte Biol. 36: 689–701PubMedGoogle Scholar
  226. Leech JA, Gervais A & Ruben FL (1987) Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. Can. Med. Assoc. J. 136: 361–365Google Scholar
  227. Leinonen M (1982) Antibody responses against pneumococcal polysaccharide antigens in vaccinated persons. Ann. Clin. Res. 14: 267–271PubMedGoogle Scholar
  228. Leontein K, Lindberg B & Lönngren J (1981) Structural studies of the capsular polysaccharide fromStreptococcus pneumoniae type 12F. Can. J. Chem. 59: 2081–2085Google Scholar
  229. Leontein K, Lindberg B, Lönngren J & Carlo DJ (1983) Structural studies of the capsular polysaccharide fromStreptococcus pneumoniae type 12A. Carbohydr. Res. 114: 257–266CrossRefPubMedGoogle Scholar
  230. Levine AM, Overturf GD, Field RF, Holdorf D, Paganini-Hill A & Feinstein DI (1979) Use and efficacy of pneumococcal vaccine in patients with Hodgkin's disease. Blood 54: 1171–1175PubMedGoogle Scholar
  231. Lichter JP, Konopka RG, Hartman MT, Mosher KM & Spragg RG (1984) The in vivo behavior of granulocytes labeled with Indium-111 in a canine model of pneumococcal pneumonia. Amer. Rev. Resp. Dis. 129: 602–606PubMedGoogle Scholar
  232. Lin KT & Lee C-J (1982) Immune response of neonates to pneumococcal polysaccharide-protein conjugate. 46: 333–342Google Scholar
  233. Lindberg B, Lönngren J, Thompson JL & Nimmich W (1972) Structural studies of theKlebsiella type 9 capsular polysaccharide. Carbohydr. Res. 25: 49–57CrossRefPubMedGoogle Scholar
  234. Lindberg B, Lönngren J & Powell DA (1977) Structural studies on the specific type-14 pneumococcal polysaccharide. Carbohydr. Res. 58: 177–186PubMedGoogle Scholar
  235. Lindberg B, Lindqvist B, Lönngren J & Powell DA (1980) Structural studies of the capsular polysaccharide fromStreptococcus pneumoniae type 1. Carbohydr. Res. 78: 111–117CrossRefPubMedGoogle Scholar
  236. Linnemann CC, First MR & Schiffman G (1986) Revaccination of renal transplant and hemodialysis recipients with pneumococcal vaccine. Arch. Intern. Med. 146: 1554–1556CrossRefPubMedGoogle Scholar
  237. Lipsky BA, Boyko EJ, Inui TS & Koepsell TD (1986) Risk factors for acquiring pneumococcal infections. Arch. Intern. Med. 146: 2179–2185CrossRefPubMedGoogle Scholar
  238. López R, García E, García P, Ronda C & Tomasz A (1982) Choline-containing bacteriophage receptors inStreptococcus pneumoniae. J. Bacteriol. 151: 1581–1590PubMedGoogle Scholar
  239. Lu C-H, Hugh R & Lee C-J (1987) Characterization of the binding of and the immune response to pneumococcal group 9 capsular polysaccharides. Molec. Immunol. 24: 427–433Google Scholar
  240. Lue C, Tarkowski A & Mestecky J (1988) Systemic immunization with pneumococcal polysaccharide vaccine induces a predominant IgA2 response of peripheral blood lymphocytes and increases both serum and secretory anti-pneumococcal antibodies. J. Immunol. 140: 3793–3800PubMedGoogle Scholar
  241. Lugowski C & Jennings HJ (1984) Structural determination of the capsular polysaccharide ofStreptococcus pneumoniae type 18C (56). Carbohydr. Res. 131: 119–129CrossRefPubMedGoogle Scholar
  242. Lund E (1962) Type 48, a new pneumococcus type. Acta. Path. Microbiol. Immunol. Scand. 56: 87–88Google Scholar
  243. Lund E (1970) On the nomenclature of the pneumococcal types. Int. J. Syst. Bacteriol. 20: 321–323Google Scholar
  244. Lund E & Munksgaard A (1967) A new pneumococcus type: type 12A. Acta Path. Microbiol. Immunol. Scand. 70: 305–310Google Scholar
  245. Lund E, Munksgaard A & Steward SM (1972) A new pneumococcus type, type 47A. Acta. Path. Microbiol. Immunol. Scand. 80: 497–500Google Scholar
  246. Mage RG & Kabat EA (1963) The combining regions of the type III pneumococcus polysaccharide and homologous antibody. Biochemistry 2: 1278–1288CrossRefPubMedGoogle Scholar
  247. Mäkelä PH, Shibakov M, Herva E, Henrichsen J, Luotonen J, Timonen M, Leinonen M, Koskela M, Pukander J, Pöntynen S, Grönroos P & Karma P (1980) Pneumococcal vaccine and otitis media. Lancet 2: 547–551PubMedGoogle Scholar
  248. Mäkelä PH, Karma P & Leinonen MK (1983) Pneumococcal vaccine and otitis media in infancy. Bull. Eur. Physiophat. Resp. 19: 235–238Google Scholar
  249. Marburg S, Jorn D, Tolman RL, Arison B, McCauley J, Kniskern PJ, Hagopian A & Vela PP (1986) Bimolecular chemistry of macromolecules: synthesis of bacterial polysaccharide conjugates withNeisseria meningitidis membrane protein. J. Amer. Chem. Soc. 108: 5282–5287CrossRefGoogle Scholar
  250. Marchessault RH, Imada K, Bluhm TL & Sudararajan PR (1980) Conformation of crystalline type III pneumococcal polysaccharide. Carbohydr. Res. 83: 287–302CrossRefPubMedGoogle Scholar
  251. Markham RB, Reed ND, Stashak PW, Prescott B, Amsbaugh DF & Baker PJ (1977) Effect of concanavalin A on lymphocyte interactions involved in the antibody response to type III pneumococcal polysaccharide. II. Ability of suppressor T cells to act on both B cells and amplifier T cells to limit the magnitude of the antibody response. J. Immunol. 119: 1163–1168PubMedGoogle Scholar
  252. Matter L, Wilhelm JA, Angehrn W, Skvaril F & Schopfer K (1985) Selective antibody deficiency and recurrent pneumococcal bacteremia in a patient with Sjögrens syndrome, hyperimmunoglobulinemia G and deficiencies of IgG2 and IgG4. N. Engl. J. Med. 312 (1985) 1039–1042PubMedGoogle Scholar
  253. Matthay KK, Mentzer WC, Wara DW, Preisler HK, Lameris NB & Ammann AJ (1981) Evaluation of opsonic requirements for phagocytosis ofStreptococcus pneumoniae serotypes VII, XIV, and XIX by chemoluminescence assay. Infect. Immun. 31: 228–235PubMedGoogle Scholar
  254. McDaniel LS, Scott G, Widenhofer K, Carroll JM & Briles DE (1986) Analysis of a surface protein ofStreptococcus pneumoniae recognised by protective monoclonal antibodies. Microb. Pathogen. 1: 519–531CrossRefGoogle Scholar
  255. McDaniel LS, Waltman WD, Gray B & Briles DE (1987) A protective monoclonal antibody that reacts with a novel antigen of pneumococcal teichoic acid. Microb. Pathogen. 3: 249–260CrossRefGoogle Scholar
  256. McDaniel LS & Briles DE (1988) A pneumococcal surface protein (Psp B) that exhibits the same protease sensitivity as streptococcal R antigen. Infect. Immun. 56: 3001–3003PubMedGoogle Scholar
  257. McDonald E, Jarrett MP, Schiffman G & Grayzel AI (1984) Persistence of pneumococcal antibodies after immunization in patients with systemic lupus erythematosus. J. Rheumatol. 11: 306–308PubMedGoogle Scholar
  258. McNamara MK, Ward RE & Kohler H (1984) Monoclonal idiotype vaccine againstStreptococcus pneumoniae infection. Science 226: 1325–1326PubMedGoogle Scholar
  259. Mellencamp MA, Preheim LC & McDonald TL (1987) Isolation and characterization of circulating immune complexes from patients with pneumococcal pneumonia. Infect. Immun. 55: 1737–1742PubMedGoogle Scholar
  260. Milligan GN & Braley-Mullen H (1989) Regulation of IgG responses by helper and suppressor T cells activated by pneumococcal capsular polysaccharides. Cellul. Immunol. 119: 222–232Google Scholar
  261. Minor DR, Schiffman G & McIntosh LS (1979) Response of patients with Hodgkin's disease to pneumococcal vaccine. Ann. Intern. Med. 90: 887–892PubMedGoogle Scholar
  262. Mold C, Nakayama S, Holzer TJ, Gewurz H & Du Clos TW (1981) C-reactive protein is protective againstStreptococcus pneumoniae infection in mice. J. Exp. Med. 154: 1703–1708CrossRefPubMedGoogle Scholar
  263. Mold C, Edwards KM & Gewurz H (1982) Effect of C-reactive protein on the complement-mediated stimulation of human neutrophils byStreptococcus pneumoniae serotypes 3 and 6. Infect. Immun. 37: 987–992PubMedGoogle Scholar
  264. Mold C, Kingzette M & Gewurz H (1984) C-reactive protein inhibits pneumococcal activation of the alternative pathway by increasing the interaction between factor H and C3b. J. Immunol. 133: 882–885PubMedGoogle Scholar
  265. Moore DH, Shackelford PG, Robson AM & Rose MD (1980) Recurrent pneumococcal sepsis and defective opsonization after pneumococcal capsular polysaccharide vaccine in a child with nephrotic syndrome. J. Pediatr. 96: 882–885PubMedGoogle Scholar
  266. Moreau M, Richards JC & Perry MB (1988a) Application of high-resolution n.m.r. spectroscopy to the elucidation of the structure of the specific capsular polysaccharide ofStreptococcus pneumoniae type 7F. Carbohydr. Res. 182: 79–99CrossRefPubMedGoogle Scholar
  267. Moreau M, Richards JC, Perry MB & Kniskern PJ (1988b) Structural analysis of the specific capsular polysaccharide ofStreptococcus pneumoniae type 45 (American type 72). Biochemistry 27: 6820–6829PubMedGoogle Scholar
  268. Morell A, Sidiropoulos D, Herrmann U, Christensen KK, Christensen P, Prellner K, Fey H & Skvaril F (1986) IgG subclasses and antibodies to group B streptococci, pneumococci, and tetanus toxoid in preterm neonates after intravenous infusion of immunoglobulin to the mothers. Pediatr. Res. 20: 933–936PubMedGoogle Scholar
  269. Moreno C (1987) Carbohydrates as immunogens and tolerogens. Antibody versus cell-mediated immune responses. In: Bell R & Torrigiani G (Eds) Towards Better Carbohydrate Vaccines. (pp 263–277) J. Wiley & Sons Ltd.Google Scholar
  270. Moshier DE, Feeney AJ & Scherle P (1987) The physiology of B lymphocytes capable of generating anti-polysaccharide antibody responses. In Bell R & Torrigiani G (Eds) Towards Better Carbohydrate Vaccines (pp 243–261) J. Wiley & Sons Ltd.Google Scholar
  271. Mosser JL & Tomasz A (1970) Choline-containing teichoic acid as a structural component of pneumococcal cell wall and its role in sensitivity to lysis by an autolytic enzyme. J. Biol. Chem. 245: 287–298PubMedGoogle Scholar
  272. Moulin A, Fleurette J & Ekong G (1979) Sérotypie des pneumocoques isolés dans les produits pathologiques au cours de deux périodes 1972–1977 et 1978. Path. Biol. 27: 567–570Google Scholar
  273. Mufson MA, Kruss DM, Wasil RE & Metzger WI (1974) Capsular types and outcome of bacteremic disease in the antibiotic era. Arch. Intern. Med. 134: 505–510CrossRefPubMedGoogle Scholar
  274. Mufson MA, Oley G & Hughey D (1982) Pneumococcal disease in a medium-sized community in the United States. J. Amer. Med. Assoc. 248: 1486–1489CrossRefGoogle Scholar
  275. Mufson MA, Krause HE & Schiffman G (1983) Long-term persistence of antibody following immunization with pneumococcal polysaccharide vaccine. Proc. Soc. Exp. Biol. Med. 173: 270–275PubMedGoogle Scholar
  276. Mufson MA, Krause HE & Schiffman G (1984) Reactivity and antibody responses of volunteers given two or three doses of pneumococcal vaccine. Proc. Soc. Exp. Biol. Med. 177: 220–225PubMedGoogle Scholar
  277. Mufson MA, Krause HE, Schiffman G & Hughey DF (1987) Pneumococcal antibody levels one decade after immunization of healthy adults. Amer. J. Med. Sci. 293: 279–289PubMedGoogle Scholar
  278. Murphy TF & Fine BC (1984) Bacteremic pneumococcal pneumonia in the elderly. Amer. J. Med. Sci. 288: 114–118PubMedGoogle Scholar
  279. Musher DM, Chapman AJ, Goree A, Jonsson S, Briles D & Baughn RE (1986) Natural and vaccine-related immunity toStreptococcus pneumoniae. J. Infect. Dis. 154: 245–256PubMedGoogle Scholar
  280. Nakayama S, Gewurz H, Holzer T, Du Clos TW & Mold C (1983) The role of the spleen in the protective effect of C-reactive protein inStreptococcus pneumoniae infection. Clin. Exp. Immunol. 54: 319–326PubMedGoogle Scholar
  281. Nikoskelainen J, Koskela M, Forsström J, Kasanen A, Leinonen M (1985) Persistence of antibodies to pneumococcal vaccine in patients with chronic renal failure. Kidney Intern. 28: 672–677Google Scholar
  282. Nohr CW, Latter DA, Meakins JL & Christou NV (1986) In vivo and in vitro humoral immunity in surgical patients: antibody response to pneumococcal polysaccharide. Surgery 100: 229–238PubMedGoogle Scholar
  283. Nurmi T & Koskela P (1988) Immunosuppressive effect of pneumococcal vaccine contaminated with blood-group-A-like substance. Lancet 1: 771PubMedGoogle Scholar
  284. Ofek I & Sharon N (1988) Lectinophagocytosis: a molecular mechanism of recognition between cell surface sugars and lectins in the phagocytosis of bacteria. Infect. Immun. 56: 539–547PubMedGoogle Scholar
  285. Offenbartl K, Gullstrand P, Prellner K, Christensen P & Henrichsen J (1986) Comparison of antibody levels and protective efficacy against pneumococci in two immunoglobulin preparations for intravenous use. Int. Arch. Allergy Appl. Immun. 80: 307–311Google Scholar
  286. Ohno N, Yadomae T & Miyazaki T (1980) The structure of the type specific polysaccharide of pneumococcus type XIX. Carbohydr. Res. 80: 297–304CrossRefGoogle Scholar
  287. Pallares R, Gudiol F, Liñares J, Ariza J, Rufi G, Murguni L, Dorc J & Viladrich PF (1987) Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin resistant pneumococci. N. Engl. J. Med. 317: 18–22PubMedGoogle Scholar
  288. Panza L, Ronchetti F, Russo G & Toma L (1987) Synthesis of the trisaccharide component of the repeating unit of the capsular polysaccharide ofStreptococcus pneumoniae type 19F. J. Chem. Soc. Perkin I: 2745–2747Google Scholar
  289. Panza L, Ronchetti F & Toma L (1988)Streptococcus pneumoniae type 19A polysaccharide. Synthesis of the trisaccharide component of the repeating unit. Carbohydr. Res. 180: 242–245Google Scholar
  290. Pappenheimer AM, Reed WP & Brown R (1968) Quantitative studies of the specificity of anti-pneumococcal antibodies, type III and VIII -3. Binding of a labeled oligosaccharide derived from S8 by anti-S8 antibodies. J. Immunol. 100: 1237–1244PubMedGoogle Scholar
  291. Pasanen VJ (1986) The immune response to pneumococcal polysaccharide type III is followed by increased production of an antibody antifactor. Scand. J. Immunol. 23: 309–318PubMedGoogle Scholar
  292. Paton JC, Rowan-Kelly B & Ferrante A (1984) Activation of human complement by the pneumococcal toxin pneumolysin. Infect. Immun. 43: 1085–1087PubMedGoogle Scholar
  293. Paton JC, Toogood IR, Cockington RA & Hansman D (1986) Antibody response to pneumococcal vaccine in children aged 5 to 15 years. Amer. J. Dis. Child. 140: 135–138PubMedGoogle Scholar
  294. Paul WE, Katz DH & Benacerraf B (1971) Augmented anti-SIII antibody responses to an SIII-protein conjugate. J. Immunol. 107: 685–688PubMedGoogle Scholar
  295. Paulsen H, Helpap B & Lorentzen JP (1988) Synthese von Trisaccharid-einheiten der Kapselpolysaccharide vonStreptococcus pneumoniae. Carbohydr. Res. 179: 173–197CrossRefPubMedGoogle Scholar
  296. Pazur JH, Erickson MS, Tay ME & Allen PZ (1983) Isomeric, anti-rhamnose antibodies having specificity for rhamnosecontaining, streptococcal heteroglycans. Carbohydr. Res. 124: 253–263CrossRefPubMedGoogle Scholar
  297. Pedersen FK (1983) Antibody response to pneumococcal vaccine in splenectomized children. Acta Pathol. Microbiol. Immunol. Scand. C 91: 169–180PubMedGoogle Scholar
  298. Pedersen FK & Henrichsen J (1982) Detection of antibodies to pneumococcal capsular polysaccharides by enzyme-linked immunosorbent assay. J. Clin. Microbiol. 15: 372–378PubMedGoogle Scholar
  299. Pennington J & Feizi T (1982) Horse anti-type XIV pneumococcus sera behave as cold agglutinins recognizing developmentally regulated antigens apart from the Ii antigens on human erythrocytes. Vox Sanguinis 43: 253–258PubMedGoogle Scholar
  300. Perry MB, Daoust V & Lowe R (1980) Abstr. W.H.O. 3rd. Int. Conf. on Immunity, Immunization and Cerebrospinal Meningitis, MarburgGoogle Scholar
  301. Perry MB, Daoust V & Carlo DJ (1981) The specific capsular polysaccharide ofStreptococcus pneumoniae type 9V. Can. J. Biochem. 59: 524–533PubMedGoogle Scholar
  302. Perry MB, Bundle DR, Daoust V & Carlo DJ (1982) The specific capsular polysaccharide ofStreptococcus pneumoniae type 15F. Mol. Immunol. 19: 235–246CrossRefPubMedGoogle Scholar
  303. Perry MB, Bundle DR, Daoust V & Carlo DJ (1983) ref. 269. In: Kenne L & Lindberg B (Eds) ‘The Polysaccharides’, Vol. 2 (pp 287–363) Acad. Press Inc.Google Scholar
  304. Pirovino M, Lydick E, Grob PJ, Arrenbrecht S, Altorfer J & Schmid M (1984) Pneumococcal vaccination: the response of patients with alcoholic liver cirrhosis. Hepathology 4: 946–949Google Scholar
  305. Plotkowski M-C, Pluchelle E, Beck G, Jaquot J & Hannoun C (1986) Adherence of type IStreptococcus pneumoniae to tracheal epithelium of mice infected with Influenza A/PR8 virus. Amer. Rev. Resp. Dis. 134: 1040–1044PubMedGoogle Scholar
  306. Pönkä A & Leinonen M (1982) Adverse reactions to polyvalent pneumococcal vaccine. Scand. J. Infect. Dis. 14: 67–71PubMedGoogle Scholar
  307. Porro M, Costantino P, Viti S, Vannozzi F, Naggi A & Torri G (1985) Specific antibodies to diphtheria toxin and type 6A pneumococcal capsular polysaccharide induced by a model of semi-synthetic glycoconjugate antigen. Molec. Immunol. 22: 907–919Google Scholar
  308. Prellner K (1981) C1q binding and complement activation by capsular and cell wall components ofS. pneumoniae type XIX. Acta Pathol. Microbiol. Immunol. Scand. C89: 359–364Google Scholar
  309. Prellner K, Kalm O & Pedersen FK (1984) Pneumococcal antibodies and complement during and after periods of recurrent otitis. Int. J. Pediat. Otolaryngol. 7: 39–49Google Scholar
  310. Prellner K, Braconier JH & Sjöholm AG (1985) Combined IgG2, IgG4 and IgA deficiency: low C1q concentrations and the presence of excess C1r and C1s in an adult patient with recurrent pneumococcal infections. Acta Path. Microbiol. Immunol. C 93: 257–263Google Scholar
  311. Prellner K, Christensen P, Kalm O & Offenbartl K (1986) The effect of serial intravenous immunoglobulin infusion on type-specific anti-pneumococcal antibodies in children. Acta Path. Microbiol. Immunol. Scand. C 94: 207–211Google Scholar
  312. Prober CG, Frayha H, Klein M & Schiffman G (1983) Immunologic responses of children to serious infections withStreptococcus pneumoniae. J. Infect. Dis. 148: 427–435PubMedGoogle Scholar
  313. Rabinovich RA, Koethe SM, Kalbfleisch JH, Preheim LC & Rytel MW (1986) Relationship between alternative complement pathway activation, C-reactive protein, and pneumococcal infection. J. Clin. Microbiol. 23: 56–61Google Scholar
  314. Rao EV, Buchanan JG & Baddiley J (1966) The type-specific substance from pneumococcus type 10A (34). Biochem. J. 100: 801–810; 811–814PubMedGoogle Scholar
  315. Rebers PA & Heidelberger M (1961) The specific polysaccharide of type VI pneumococcus. 2. The repeating unit. J. Amer. Chem. Soc. 83: 3056–3059CrossRefGoogle Scholar
  316. Rebers PA, Hurwitz E & Heidelberger M (1961) Immunochemistry of the pneumococcal types II, V, and VI. 2. Inhibition tests in the type VI precipitating system. J. Bacteriol. 82: 920–926PubMedGoogle Scholar
  317. Reed WP, Stromquist DL & Williams RC (1983) Agglutination and phagocytosis of pneumococci by immunoglobulin G antibodies of restricted heterogeneity. J. Lab. Clin. Med. 101: 847–856PubMedGoogle Scholar
  318. Reed WP & Albright EL (1986) Opsonic requirements for hepatic clearance of pneumococci. Infect. Immun. 52: 499–503PubMedGoogle Scholar
  319. Reeves RE & Goebel WF (1941) Chemoimmunological studies on the soluble specific substance of pneumococcus. V. The structure of the type III polysaccharide. J. Biol. Chem. 139: 511–519Google Scholar
  320. Richards JC, Perry MB & Carlo DJ (1983) The specific capsular polysaccharide ofStreptococcus pneumoniae type 20. Can. J. Biochem. Cell Biol. 61: 178–190PubMedGoogle Scholar
  321. Richards JC, Perry MB & Kniskern PJ (1984a) Structural analysis of the specific polysaccharide ofStreptococcus pneumoniae type 9L (American type 49). Can. J. Biochem. Cell Biol. 62: 1309–1320PubMedGoogle Scholar
  322. Richards JC, Perry MB & Kniskern PJ (1984b) The specific capsular polysaccharide ofStreptococcus pneumoniae type 33F. Can. J. Biochem. Cell Biol. 62: 666–677PubMedGoogle Scholar
  323. Richards JC, Perry MB & Kniskern PJ (1985) The structure of the specific capsular polysaccharide ofStreptococcus pneumoniae type 11F (American type 11). Can. J. Biochem. Cell Biol. 63: 953–968PubMedGoogle Scholar
  324. Richards JC & Perry MB (1986) Application of two dimensional N.M.R. methods to the structural elucidation of complex polysaccharide antigens. The structure of the capsular polysaccharide ofStreptococcus pneumoniae type 22F. Abstr. XIIIth Int. Carbohydr. Symp., Itaca, N.Y., U.S.A. p 192Google Scholar
  325. Richards JC & Perry MB (1988) Structure of the specific capsular polysaccharide ofStreptococcus pneumoniae type 23F (American type 23). Biochem. Cell Biol. 66: 758–771PubMedGoogle Scholar
  326. Riesenfeld-Orn I, Wolpe S, Garcia-Bustos JF, Hoffmann MK & Tuomanen E (1989) Production of interleukin-1 but not of tumor necrosis factor by human monocytes stimulated with pneumococcal cell surface components. Infect. Immun. 57: 1890–1893PubMedGoogle Scholar
  327. Rijkers GT & Moshier DE (1985) Pneumococcal polysaccharides induce antibody formation by human B lymphocytes in vitro. J. Immunol. 135: 1–4PubMedGoogle Scholar
  328. Rijkers GT, Dollekamp EG & Zegers BJM (1987) The in vitro B-cell response to pneumococcal polysaccharides in adults and neonates. Scand. J. Immunol. 25: 447–452PubMedGoogle Scholar
  329. Riley ID, Lehmann D, Alpers MP, de C. Marshall TF, Gratten H & Smith D (1986) Pneumococcal vaccine prevents death from acute lower-respiratory-tract infections in Papua New Guinean children. Lancet 2: 877–881PubMedGoogle Scholar
  330. Ripley-Petzoldt ML, Giebink GS, Juhn SK, Aeppli D, Tomasz A & Tuomanen E (1988) The contribution of pneumococcal cell wall to the pathogenesis of experimental otitis media. J. Infect. Dis. 157: 245–255PubMedGoogle Scholar
  331. Roberton DM, Björkander J, Henrichsen J, Söderström T & Hanson LÅ (1989) Enhanced IgG1 and IgG3 responses to pneumococcal polysaccharides in isolated IgA deficiency. Clin. Exp. Immunol. 75: 201–205PubMedGoogle Scholar
  332. Robbins JB (1978) Vaccines for the prevention of encapsulated bacterial diseases: current status, problems and prospects for the future. Immunochemistry 15: 839–854PubMedGoogle Scholar
  333. Robbins JB, Austrian R, Lee C-J, Rastogi SC, Schiffman G, Henrichsen J, Mäkelä PH, Broome CV, Facklam RR, Tiesjema RH & Parke JC (1983) Considerations for formulating the second-generation pneumococcal polysaccharide vaccine with emphasis on the cross-reactive types within groups. J. Infect. Dis. 148: 1136–1159PubMedGoogle Scholar
  334. Robert D, Ivanoff B, Fontanges R, Normier G, Pinel AM & Dussourd d'Hinterland L (1982) Study of the mode of action of ribosomal vaccines fromKlebsiella andStreptococcus pneumoniae and their ribonucleic and protein fractions using passive immunization. Microbiol. Immunol. 26: 933–940PubMedGoogle Scholar
  335. Rogers DE (1960) Host mechanisms which act to remove bacteria from the blood stream. Bacteriol. Rev. 24: 50–66PubMedGoogle Scholar
  336. Roghmann KJ, Tabloski PA, Benley DW & Schiffman G (1987) Immune response of elderly adults to pneumococcus: variation by age, sex, and functional impairment. J. Gerontol. 42: 265–270PubMedGoogle Scholar
  337. Rosén C, Christensen P, Hovelius B & Prellner K (1984) A longitudinal study of the nasopharyngeal carriage of pneumococci as related to pneumococcal vaccination in children attending day-care centres. Acta Otolaryngol. 98: 524–532PubMedGoogle Scholar
  338. Ruben FL & Uhrin M (1985) Specific immunoglobulin-class antibody responses in the elderly before and after 14-valent pneumococcal vaccine. J. Infect. Dis. 151: 845–849PubMedGoogle Scholar
  339. Rynnel-Dagöö B, Freijd A, Hammarström L, Oxelius V, Persson MAA & Smith CIE (1986) Pneumococcal antibodies of different immunoglobulin subclasses in normal and IgG subclass deficient individuals of various ages. Acta Otolaryngol. 101: 146–151PubMedGoogle Scholar
  340. Rytel MW & Preheim LC (1986) Antigen detection in the diagnosis and in the prognostic assessment of bacterial pneumonias. Diagn. Microbiol. Infect. Dis. 4: 35S-46SPubMedGoogle Scholar
  341. Rytel MW, Dailey MP, Schiffman G, Hoffmann RG & Piering WF (1986) Pneumococcal vaccine immunization of patients with renal impairment. Proc. Soc. Exp. Biol. Med. 182: 468–473PubMedGoogle Scholar
  342. Sande MA, Sande ER, Woolwine JD, Hackbath CJ & Small PM (1987) The influence of fever on the development of experimentalStreptococcus pneumoniae meningitis. J. Infect. Dis. 156: 849–850PubMedGoogle Scholar
  343. Sarvas H, Rautonen N, Sipinen S & Mäkelä O (1989) IgG Subclasses of pneumococcal antibodies — effect of allotype G2m(n). Scand. J. Immunol. 29: 229–237PubMedGoogle Scholar
  344. Schatz DA & Barrett DJ (1987) Evolution of the subclass of IgG antibody to type 3 pneumococcal polysaccharide during childhood. Clin. Exp. Immunol. 70: 449–455PubMedGoogle Scholar
  345. Schiffman G, Bornstein DL & Austrian R (1971) Capsulation of pneumococcus with soluble cell wall-like polysaccharide. II. Nonidentity of cell wall and soluble cell wall-like polysaccharides derived from the same and from different pneumococcal strains. J. Exp. Med. 134: 600–617CrossRefPubMedGoogle Scholar
  346. Schiffman G (1983a) Pneumococcal polysaccharide vaccine: composition, antibody protective levels and use for the evaluation of the functioning of the immune system. Med. Microbiol. 2: 145–155Google Scholar
  347. Schiffman G (1983b) Pneumococcal vaccine: a tool for the evaluation of the B-cell function of the immune system. Proc. Soc. Exp. Biol. Med. 174: 309–315PubMedGoogle Scholar
  348. Schmid G, Smith RP, Baltch AL, Hall CA & Schiffman G (1979) Antibody response to pneumococcal vaccine in multiple myeloma. Clin. Res. 27: 355A.Google Scholar
  349. Schneerson R, Robbins JB, Chu C, Sutton A, Vann W, Vickers JC, London WT, Curfman B, Hardegree MC, Shiloach J & Rastogi SC (1984) Serum antibody responses of juvenile and infant rhesus monkeys injected withHaemophilus influenzae type b and pneumococcus type 6A capsular polysaccharideprotein conjugates. Infect. Immun. 45: 582–591PubMedGoogle Scholar
  350. Schneerson R, Robbins JB, Parke JC, Bell C, Schlesselman JJ, Sutton A, Wang Z, Schiffman G, Karpas A & Shiloach J (1986) Quantitative and qualitative analysis of serum antibodies elicited in adults byHaemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates. Infect. Immun. 52: 519–528PubMedGoogle Scholar
  351. Schneerson R, Robbins JB, Szu SC & Yang Y (1987) Vaccines composed of polysaccharide-protein conjugates: current status, unanswered questions, and prospects for the future. In: Bell R & Torrigiani G (Eds) Towards Better Carbohydrate Vaccines (pp 307–332) J. Wiley & Sons Ltd.Google Scholar
  352. Schwartz JS (1982) Pneumococcal vaccine: clinical efficacy and effectiveness. Ann. Intern. Med. 96: 208–220PubMedGoogle Scholar
  353. Schweinle JE (1986) Pneumococcal intracellular killing is abolished by polysaccharides despite serum complement activity. Infect. Immun. 54: 876–881PubMedGoogle Scholar
  354. Sestini P, Nencioni L, Villa L, Boraschi D & Tagliabue A (1988) IgA-driven antibacterial activity againstStreptococcus pneumoniae by mouse lung lymphocytes. Amer. Rev. Resp. Dis. 137: 138–143PubMedGoogle Scholar
  355. Shabarova ZA, Buchanan JG & Baddiley J (1962) The composition of pneumococcus type-specific substances containing phosphorus. Biochim. Biophys. Acta 57: 146–148CrossRefPubMedGoogle Scholar
  356. Shildt RA, Rubin RR, Schiffman G & Giolma P (1981) Polyvalent pneumococcal immunization of patients with plasma cell dyscrasias. Cancer 48: 1377–1380PubMedGoogle Scholar
  357. Shurin PA, Giebink GS, Wegman DL, Ambrosino D, Rholl J, Overman M, Bauer T & Siber G (1988) Prevention of pneumococcal otitis media in chinchillas with human bacterial polysaccharide immune globulin. J. Clin. Microbiol. 26: 755–759PubMedGoogle Scholar
  358. Siber GR, Ambrosino DM, McIver J, Ervin TJ, Schiffman G, Sallan S & Grady GF (1984) Preparation of human hyperimmune globulin toHaemophilus influenzae b,Streptococcus pneumoniae, andNeisseria meningitidis. Infect. Immun. 45: 248–254PubMedGoogle Scholar
  359. Siber GR, Gorham C, Martin P, Corkery JC & Schiffman G (1986) Antibody response to pretreatment immunization and post-treatment boosting with bacterial polysaccharide vaccines in patients with Hodgkin's disease. Ann. Intern. Med. 104: 467–475PubMedGoogle Scholar
  360. Simberkoff MS, Schiffman G, Katz LA, Spicehandler JR, Moldover NH & Rahal JJ (1980) Pneumococcal capsular polysaccharide vaccination in adult chronic hemodialysis patients. J. Lab. Clin. Med. 96: 363–370PubMedGoogle Scholar
  361. Simberkoff MS, Schiffman G, Spicehandler JR, Moldover NH & Rahal JJ (1983) Radioimmunoassay and opsonic antibody responses to pneumococcal capsular polysaccharide vaccine in serum and ascitic fluid of cirrhotic patients. Clin. Microbiol. 18: 154–159Google Scholar
  362. Simberkoff MS, El Sadr W, Schiffman G & Rahal JJ (1984)Streptococcus pneumoniae infections and bacteremia in patients with acquired immune deficiency syndrome, with report of a pneumococcal vaccine failure. Ann. Rev. Resp. Dis. 130: 1174–1176Google Scholar
  363. Simberkoff MS, Cross AP, Al-Ibrahim M, Baltch AL, Geiseler PJ, Nadler J, Richmond AS, Smith RP, Schiffman G, Shepard DS & van Eeckhout JP (1986) Efficacy of pneumococcal vaccine in high-risk patients. Results of a vetrans administration cooperative study. N. Engl. J. Med. 315: 1318–1327PubMedGoogle Scholar
  364. Sims RV, Steinmann WC, McConville JH, King LR, Zwick WC & Schwartz JS (1988) The clinical effectiveness of pneumococcal vaccine in the elderly. Ann. Intern. Med. 108: 653–657PubMedGoogle Scholar
  365. Slaghek TM, van Vliet MJ, Maas AAM, van Oijen AH, Kamerling JP & Vliegenthart JFG (1988) Synthesis of two derivatives of a common trisaccharide fragment of the capsular polysaccharide ofStreptococcus pneumoniae types 6A and 6B. Abstr. XIVth Int. Carbohydr. Symp., Stockholm, p 246Google Scholar
  366. Snippe H, van Houte AJ, van Dam JEG, de Reuver MJ, Jansze M & Willers JMN (1983a) Immunogenic properties in mice of hexasaccharide from the capsular polysaccharide ofStreptococcus pneumoniae type 3. Infect. Immun. 40: 856–861PubMedGoogle Scholar
  367. Snippe H, van Dam JEG, van Houte AJ, Willers JMN, Kamerling JP & Vliegenthart JFG (1983b) Preparation of a semisynthetic vaccine toStreptococcus pneumoniae type 3. Infect. Immun. 43: 842–844Google Scholar
  368. Sørensen UBS, Agger R, Bennedsen J & Henrichsen J (1984) Phosphorylcholine determinants in six pneumococcal capsular polysaccharides detected by monoclonal antibody. Infect. Immun. 43: 876–878PubMedGoogle Scholar
  369. Sørensen UBS, Blom J, Birch-Andersen A & Henrichsen J (1988) Ultrastructural localization of capsules, cell wall polysaccharide, cell wall proteins, and F-antigen in pneumococci. Infect. Immun. 56: 1890–1896Google Scholar
  370. Steinfort C, Wilson R, Mitchell T, Feldman C, Rutman A, Todd H, Sykes D, Walker J, Saunders K, Andrew PW, Boulnois GJ & Cole PJ (1989) Effect ofStreptococcus pneumoniae on human respiratory epithelium in vitro. Infect. Immun. 57: 2006–2013PubMedGoogle Scholar
  371. Steinitz M, Tamir S, Ferne M & Goldfarb A (1986) A protective human monoclonal IgA antibody produced in vitro: antipneumococcal antibody engendered by Epstein-Barr virusimmortalized cell line. Eur. J. Immunol. 16: 187–193PubMedGoogle Scholar
  372. Stephens CG, Williams RC & Reed WP (1977) Classical and alternative complement pathway activation by pneumococci. Infect. Immun. 17: 296–302PubMedGoogle Scholar
  373. Stout JT, Strickland FM & Cerny J (1985) Regulation of idiotype expression. I. The effect of antigen dose on expression of certain T15 idiotypes during primary IgM response toS. pneumoniae R36a. J. Immunol. 134: 1926–1929PubMedGoogle Scholar
  374. Sugawara T & Igarashi K (1988) Synthesis of a trisaccharide component of the capsular polysaccharide ofStreptococcus pneumoniae type 19F. Carbohydr. Res. 172: 195–207CrossRefPubMedGoogle Scholar
  375. Sullivan JL, Ochs HD, Schiffman G, Hammerschlag MR, Miser J, Vichinsky E & Wedgwood RJ (1978) Immune response after splenectomy. Lancet 1978: 178–181Google Scholar
  376. Suzuki H & Hehre EJ (1964) The differentation of serotype A and B dextrans by means of partial acetolysis. Arch. Biochem. Biophys. 104: 305–313PubMedGoogle Scholar
  377. Szu SC, Lee C-J, Carlo DJ & Henrichsen J (1981) Immunochemical characterization of cross-reactivity of pneumococcal group 9 capsular polysaccharide types 9N, 9A, 9L, and 9V. Infect. Immun. 31: 371–379PubMedGoogle Scholar
  378. Szu SC, Lee C-J, Parke JC, Schiffman G, Henrichsen J, Austrian R, Rastogi SC & Robbins JB (1982) Cross-immunogenicity of pneumococcal group 9 capsular polysaccharides in adult volunteers. Infect. Immun. 35: 777–782PubMedGoogle Scholar
  379. Szu SC, Clarke S & Robbins JB (1983) Protection against pneumococcal infection in mice conferred by phosphocholinebinding antibodies: specificity of the phosphocholine binding and relation to several types. Infect. Immun. 39: 993–999PubMedGoogle Scholar
  380. Szu SC, Schneerson R & Robbins JB (1986) Rabbit antibodies to the cell wall polysaccharide ofStreptococcus pneumoniae fail to protect mice from lethal challenge with encapsulated pneumococci. Infect. Immun. 54: 448–455PubMedGoogle Scholar
  381. Taylor CE, Stashak PW, Caldes G, Prescott B, Chused TE, Brooks A & Baker PJ (1983) Activation of antigen-specific suppressor T cells by B cells from mice immunized with type III pneumococcal polysaccharide. J. Exp. Med. 158: 703–717CrossRefPubMedGoogle Scholar
  382. Taylor CE, Stashak PW, Chiang J, Leiserson WM, Caldes G, Prescott B & Baker PJ (1984a) Characteristics of amplifier T cells involved in the antibody response to the capsular polysaccharide of type IIIStreptococcus pneumoniae. J. Immunol. 132: 3103–3108PubMedGoogle Scholar
  383. Taylor CE, Stashak PW, Caldes G, Prescott B, Fowlkes BJ & Baker PJ (1984b) Lectin-induced modulation of the antibody response to type III pneumococcal polysaccharide. Cell. Immunol. 83: 26–33CrossRefPubMedGoogle Scholar
  384. Taylor CE & Baker PJ (1985) Production of soluble suppressor factor by spleen cells from mice immunized with type III pneumococcal polysaccharide. J. Immunol. 135: 2551–2556PubMedGoogle Scholar
  385. Toews GB & Vial WC (1984) The role of C5 in polymorphonuclear leukocyte recruitment in response toStreptococcus pneumoniae. Amer. Rev. Respir. Dis. 129: 82–86Google Scholar
  386. Tomasz A (1981) Surface components ofStreptococcus pneumoniae. Rev. Infect. Dis. 3: 190–211PubMedGoogle Scholar
  387. Tuomanen E (1986) Induction of meningeal inflammation by diverse bacterial cell walls. Eur. J. Clin. Microbiol. 5: 682–685CrossRefPubMedGoogle Scholar
  388. Tuomanen E, Liu H, Hengstler B, Zak O & Tomasz A (1985) The induction of meningeal inflammation by components of the pneumococcal cell wall. J. Infect. Dis. 151: 859–868PubMedGoogle Scholar
  389. Tuomanen E, Hengstler B, Zak O & Tomasz A (1986) The role of complement in inflammation during experimental pneumococcal meningitis. Microb. Pathogen. 1: 15–32CrossRefGoogle Scholar
  390. Urbain J, Francotte M, Franssen JD, Hienaux J, Leo O, Moser M, Slaoui M, Urbain-Vansanten G, Van Acker A & Wikler M (1983) From clonal selection to immune networks: induction of silent idiotypes. Ann. N.Y. Acad. Sci. 418: 1–8PubMedGoogle Scholar
  391. Van Dam GJ, Verheul AFM, Zigterman GJWJ, de Reuver MJ & Snippe H (1989a) Estimation of the avidity of antibodies in polyclonal antisera againstStreptococcus pneumoniae type 3 by inhibition ELISA. Mol. Immunol. 26: 269–274PubMedGoogle Scholar
  392. Van Dam GJ, Verheul AFM, Zigterman GJWJ, de Reuver MJ & Snippe H (1989b) Nonionic block polymer enhance on the avidity of antibodies in polyclonal antisera againstStreptococcus pneumoniae type 3 in normal and Xid mice. J. Immunol. in pressGoogle Scholar
  393. Van Dam JEG, Breg J, Komen R, Kamerling JP & Vliegenthart JFG (1989a) Isolation and structural studies of phosphatecontaining oligosaccharides from alkaline and acid hydrolysates ofStreptococcus pneumoniae type 6B capsular polysaccharide. Carbohydr. Res. 187: 267–286PubMedGoogle Scholar
  394. Van Dam JEG, Maas AAM, Kamerling JP, Vliegenthart JFG, Verheul AFM & Snippe H (1989b) Preparation of a semisynthetic vaccine toStreptococcus pneumoniae serotype 14 (in preparation)Google Scholar
  395. Van Steijn AMP, Jetten M, Kamerling JP & Vliegenthart JFG (1989) Synthesis of tri- and tetrasaccharide fragments of the capsular polysaccharide ofStreptococcus pneumoniae type 23F. Recl. Trav. Chim. Pays-Bas 108: 374–383Google Scholar
  396. Venkateswaran PS, Stanton N & Austrian R (1983) Type variation of strains ofStreptococcus pneumoniae in capsular serogroup 15. J. Infect. Dis. 147: 1041–1054PubMedGoogle Scholar
  397. Verheul AFM, Versteeg AA, de Reuver MJ, Jansze M & Snippe H (1989) Modulation of the immune response to pneumococcal type 14 capsular polysaccharide-protein conjugates by the adjuvant Quil A dependents on the properties of the conjugates. Infect. Immun. 57: 1078–1083PubMedGoogle Scholar
  398. Vial WC, Toews GB & Pierce AK (1984) Early pulmonary granulocyte recruitment in response toStreptococcus pneumoniae. Amer. Rev. Resp. Dis. 129: 87–91PubMedGoogle Scholar
  399. Vincent-Ballereau F, Fortier B, Armand J & Lafaix Ch (1985) Vaccination pneumococcique chez la femme enceinte en Afrique et immunité passive de l'enfant. Pathol. Biol. 33: 764–767PubMedGoogle Scholar
  400. Volanakis JE & Kaplan H (1971) Specificity of C-reactive protein for choline phosphate residues of pneumococcal C-polysaccharide. Proc. Soc. Exp. Biol. Med. 136: 612–614PubMedGoogle Scholar
  401. Volanakis JE & Narkates AJ (1983) Binding of human C4 to C-reactive protein-pneumococcal C-polysaccharide complexes during activation of the classical complement pathway. Molec. Immunol. 20: 1201–1207Google Scholar
  402. Walden P, Nagy ZA & Klein J (1985) Induction of regulatory T-lymphocyte responses by liposomes carrying MHC molecules and foreign antigen. Nature 315: 327–329PubMedGoogle Scholar
  403. Waltman WD, McDaniel LS, Andersson B, Bland L, Gray BM, Edén CS & Briles DE (1988) Protein serotyping ofStreptococcus pneumoniae based on reactivity to six monoclonal antibodies. Microb. Pathogen. 5: 159–167CrossRefGoogle Scholar
  404. Ward PA, Lepow IH & Newman LJ (1968) Bacterial factors chemotactic for polymorphonuclear leukocytes. Amer. J. Pathol. 52: 725–736Google Scholar
  405. Watkins WM (1980) Biochemistry and genetics of the ABO, Lewis, and P blood group systems. Adv. Human Genetics, 10 (1980) 1–116Google Scholar
  406. Watson MJ (1974) The type-specific substance from pneumococcus type 33B. Biochem. J. 137: 603–606PubMedGoogle Scholar
  407. Watson MJ, Tyler JM, Buchanan JG & Baddiley J (1972) The type-specific substance from pneumococcus type 13. Biochem. J. 130: 45–54PubMedGoogle Scholar
  408. Watts TH, Gaub HE & McConnell HM (1986) T-cell-mediated association of peptide antigen and major histocompatibility complex protein detected by energy transfer in an evanescent wave-field. Nature 320: 179–181CrossRefPubMedGoogle Scholar
  409. Weintrub PS, Schiffman G, Addiego JE, Matthay KK, Vichinsky E, Johnson R, Lubin B, Mentzer WC & Ammann AJ (1984) Long-term follow-up and boost immunization with polyvalent pneumococcal polysaccharide in patients with sickle cell anemia. J. Pediatr. 105: 261–263PubMedGoogle Scholar
  410. Weisholtz SJ, Hartman BJ & Robberts RB (1983) Effect of underlying disease and age on pneumococcal serotype distribution. Amer. J. Med. 75: 199–205PubMedGoogle Scholar
  411. Weitzman SA, Aisenberg AC, Siber GR & Smith DH (1978) Impaired humoral immunity in treated Hodgkin's disease. N. Engl. J. Med. 297: 245–248Google Scholar
  412. Wessels MR, Pozsgay V, Kasper DL & Jennings HJ (1987) Structure and immunochemistry of an oligosaccharide repeating unit of the capsular polysaccharide of type III group BStreptococcus. A revised structure for the type III group B streptococcal polysaccharide antigen. J. Biol. Chem. 262: 8262–8267PubMedGoogle Scholar
  413. Wessels MR & Kasper DL (1989) Antibody recognition of the type 14 pneumococcal capsule. Evidence for a conformational epitope in a neutral polysaccharide. J. Exp. Med. 169: 2121–2131CrossRefPubMedGoogle Scholar
  414. Whitehouse MW (1977) The chemical nature of adjuvants. In: Glynn LE & Stewards MW (Eds) Immunochemistry. An Advanced Textbook. (pp 572–601) John Wiley & Sons, New YorkGoogle Scholar
  415. WHO (1976) Immunological adjuvants. World Health Organization Technical Report Series 595Google Scholar
  416. Wikström MB, Dahlén G, Kaijser B & Nygren H (1984) Degradation of human immunoglobulins by proteases fromStreptococcus pneumoniae obtained from various human sources. Infect. Immun. 44: 33–37PubMedGoogle Scholar
  417. Williams JH (1987) Continuing controversy: pneumococcal vaccine and COPD. Chest 92: 193–194PubMedGoogle Scholar
  418. Williams JH & Mosher KM (1986) Pneumococcal vaccine and patients with chronic lung disease. Ann. Intern. Med. 104: 106–109PubMedGoogle Scholar
  419. Wilson D & Braley-Mullen H (1981) Antigen requirements for priming of type III pneumococcal polysaccharide specific IgG memory responses: Suppression of memory with the T-independent form of antigen. Cell. Immunol. 64: 177–186CrossRefPubMedGoogle Scholar
  420. Windebank KP, Faux JA & Chapel HM (1987) ELISA determination of IgG antibodies to pneumococcal capsular polysaccharides in a group of children. J. Immunol. Meth. 104: 143–148CrossRefGoogle Scholar
  421. Winkelstein JA (1984) Complement and the host's defense against the pneumococcus. C.R.C. Crit. Rev. Microbiol. 11: 187–208Google Scholar
  422. Winkelstein JA & Tomasz A (1978) Activation of the alternative complement pathway by pneumococcal cell wall teichoic acid. J. Immunol. 120: 174–179PubMedGoogle Scholar
  423. Winter WT & Adelsky I (1981) Pneumococcal polysaccharide conformations. Biopolymers 20: 2691–2694CrossRefPubMedGoogle Scholar
  424. Yin J-Z, Zucker MB, Clarke D, Bell MK & Thorbecke GJ (1988) Prevention by a platelet-derived factor (platelet factor 4) of induction of low dose tolerance to pneumococcal polysaccharides. Cellul. Immunol. 115: 221–227Google Scholar
  425. Yother J, Forman C, Gray BM & Briles DE (1982) Protection of mice from infection withStreptococcus pneumoniae by anti-phosphocholine antibody. Infect. Immun. 36: 184–188PubMedGoogle Scholar
  426. Zarrabi MH & Rossner F (1985) Failure of pneumococcal vaccine to prevent pneumococcal sepsis and meningitis: review of 55 reported cases. Blood 66: 217aGoogle Scholar
  427. Zigterman GJWJ, Snippe H, Jansze M, Ernste EBHW, de Reuver MJ & Willers JMN (1988) Nonionic block polymer surfactants enhance the immunogenicity of pneumococcal hexasaccharide-protein vaccines. Infect. Immun. 56: 1391–1393PubMedGoogle Scholar
  428. Zigterman GJWJ, Schotanus K, Ernste EBHW, van Dam GJ, Jansze M, Snippe H & Willers JMN (1989) Nonionic block polymer surfactants modulate the humoral immune response againstStreptococcus pneumoniae derived hexasaccharideprotein conjugates. Infect. Immun. 57: 2712–2718PubMedGoogle Scholar
  429. Zon G, Szu SC, Egan W, Robbins JD & Robbins JB (1982) Hydrolytic stability of pneumococcal group 6 (type 6A and 6B) capsular polysaccharides. Infect. Immun. 37: 89–103PubMedGoogle Scholar
  430. Zurabyan SE, Nesmeyanov VA & Khorlin AYa (1976) Synthesis of a branched tetrasaccharide 2-acetamido-4-O-β-D-galactopyranosyl-6-O-[O-β-D-galactopyranosyl-(1–4)-β-D-glucopyranosyl-]-2-desoxy-glucose. Izv. Akad. Nauk. SSSR, Ser. Khim. 6: 1421–1423 (Engl. transl. p 1363)Google Scholar

Copyright information

© Kluwer Academic Publishers 1990

Authors and Affiliations

  • Jan E. G. van Dam
    • 1
  • André Fleer
    • 2
  • Harm Snippe
    • 1
  1. 1.Eijkman-Winkler Laboratory of Medical MicrobiologyUtrecht UniversityUtrechtThe Netherlands
  2. 2.University Children's Hospital ‘Het Wilhelmina Kinderziekenhuis’UtrechtThe Netherlands

Personalised recommendations